REVIEW

FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease

David M. Ornitz^{1,3} and Pierre J. Marie²

¹Department of Molecular Biology and Pharmacology, Washington University Medical School, St. Louis, Missouri 63110, USA;

²Laboratory of Osteoblast Biology and Pathology, INSERM U349 affiliated CNRS, Hôpital Lariboisière, Paris cedex 10, France

Over the last decade the identification of mutations in the receptors for fibroblast growth factors (FGFs) has defined essential roles for FGF signaling in both endochondral and intramembranous bone development. FGF signaling pathways are essential for the earliest stages of limb development and throughout skeletal development. In this review, we examine the role of FGF signaling in bone development and in human genetic diseases that affect bone development. We also explore what is presently known about how FGF signaling pathways interact with other major signaling pathways that regulate chondrogenesis and osteogenesis.

Overview of skeletal development

Skeletal elements are formed through two distinct developmental processes. Endochondral ossification gives rise to long bones that comprise the appendicular skeleton, facial bones, vertebrae, and the lateral medial clavicles. Intramembranous ossification gives rise to the flat bones that comprise the cranium and medial clavicles. Both types of ossification involve an initial condensation of mesenchyme and the eventual formation of calcified bone. However, intramembranous bone formation accomplishes this directly, whereas endochondral ossification incorporates an intermediate step in which a cartilaginous template regulates the growth and patterning of the developing skeletal element.

Development of endochondral bones initiates shortly after the formation of the limb bud with the condensation of loose mesenchyme, marked by expression of type II collagen (Fig. 1A; Kosher et al. 1986; Nah et al. 1988). Condensing mesenchyme forms an anlage for the endochondral skeleton and can either branch or segment to form individual skeletal elements (Hall and Miyake 1992, 2000). Differentiation of condensing mesenchyme gives rise to a proliferating population of centrally local-

ized type II collagen-expressing chondrocytes and more peripherally localized type I collagen-expressing perichondrial cells (Kosher et al. 1986). At this stage, chondrocytes begin to elaborate a specialized extracellular matrix containing type II collagen. Midway between the ends of this elongated cartilaginous template, chondrocytes exit the cell cycle, hypertrophy, and begin to synthesize type X collagen in place of type II collagen (Schmid and Linsenmayer 1985).

To synthesize bone, a center of ossification forms in the mid-hypertrophic zone by neovascularization of the initially avascular cartilaginous template. The secretion and mineralization of a type I collagen-containing extracellular matrix is mediated by osteoblasts that are associated with the newly developed vasculature. As bones grow, this center of ossification propagates toward the two epiphyseal plates.

The epiphyseal growth plate consists of well-demarcated zones of cells that follow an elegant developmental program (Caplan and Pechak 1987; Hall and Miyake 1992; Olsen et al. 2000; Wagner and Karsenty 2001; Karsenty and Wagner 2002). Proximally (toward the end of a developing bone), a pool of chondrocytes (called the resting or reserve zone) supplies cells to a population of proliferating chondrocytes. Proliferating chondrocytes in turn differentiate to form a transient pool of prehypertrophic and then a more long-lived pool of hypertrophic chondrocytes. At the distal end of the epiphyseal growth plate, hypertrophic chondrocytes die by apoptosis and are replaced by trabecular bone. In this manner, hypertrophic chondrocytes provide a template for the formation of trabecular bone.

In addition to the cartilaginous and trabecular core, endochondral bone contains a hard outer shell of cortical bone (the bone collar), which surrounds the marrow cavity centrally and is contiguous with the perichondrium proximally (Caplan and Pechak 1987). The perichondrium contains precursor pools of cells that give rise to osteoblasts that line the endosteal (inner) and periosteal (outer) surface of cortical bone. Osteoblasts differentiate into osteocytes, which become embedded within cortical bone. The center of ossification in the perichondrium

³Corresponding author.

E-MAIL dornitz@pcg.wustl.edu; FAX (314) 362-7058.

Article and publication are at <http://www.genesdev.org/cgi/doi/10.1101/gad.990702>.

Figure 1. Endochondral and intramembranous bone development. (A) Schematic representation of a developing endochondral bone. Endochondral skeletal development begins with the formation of a mesenchymal condensation, expressing type II collagen (blue). Centrally, cells differentiate into chondrocytes, which hypertrophy and express type X collagen (purple). Progression to the mature growth plate accompanies development of the perichondrium (yellow), vascular invasion, and the formation of a center of ossification containing type I collagen-expressing osteoblasts (yellow). (B) Schematic representation of a developing intramembranous bone. Undifferentiated mesenchymal cells differentiate into osteoprogenitor cells expressing *Cbfa1* (pink). Osteoprogenitor cells progress to mature osteoblasts that express *Cbfa1* and type I collagen (yellow). These cells deposit and mineralize bone matrix. Osteoblasts either die by apoptosis or are embedded in the matrix, becoming osteocytes.

is aligned with the center of ossification at the chondro-osseous junction of the growth plate. A key feature of the growth of long bones is the coordination of chondrogenesis and ossification in the epiphyseal growth plate and osteogenesis in the perichondrium/periosteum (Fig. 1A).

Cranial vault development is a complex process involving cells of neural crest origin (Couly et al. 1993) and paraxial mesoderm that contribute to intramembranous bones of the cranial vault and sutures (Noden 1992; Opperman 2000). Intramembranous bone growth begins with the condensation of mesenchymal cells (Fig. 1B). Ossification centers are formed by direct bone matrix deposition-forming plates, which expand during development but do not fuse at the junction with other cranial bones (Hall and Miyake 2000). The junction between calvarial bones is a functional structure called a suture, which is responsible for the maintenance of a separation between membranous bones and for regulating the expansive growth of the skull. In the vicinity of the suture, a minority of osteogenic mesenchymal cells differentiate

into osteoprogenitor cells and then into osteoblasts that express type I collagen, bone sialoprotein, and osteocalcin, and synthesize bone matrix along the bone margins. Growth and differentiation at the suture is regulated by interactions between the mesenchyme, the osteogenic front, and the Dura mater, a tough, fibrous membrane forming the outer envelope of the brain and the inner lining of cranial bones and sutures. (see Fig. 3C below; Most et al. 1998; Opperman 2000; Morriss-Kay et al. 2001). Because sutures are the major sites of intramembranous bone growth during cranial vault development, the events occurring at the suture are essential for the regulation of intramembranous ossification (Cohen 2000a).

FGFs and FGF receptors—a brief introduction

FGFs comprise a family of 22 genes encoding structurally related proteins (Ornitz and Itoh 2001). Six subfamilies of FGFs, grouped by sequence similarities, tend to

share biochemical and functional properties and are expressed in specific spatial and developmental patterns. Four distinct FGF receptor tyrosine kinase molecules bind and are activated by most members of the FGF family. Alternative mRNA splicing produces FGF receptors with unique ligand binding properties (Johnson and Williams 1993; Ornitz et al. 1996). Alternative splicing is mostly tissue-specific, producing epithelial variants (b splice forms) and mesenchymal variants (c splice forms; Miki et al. 1992; Orr-Urtreger et al. 1993; Chellaiah et al. 1994; Naski and Ornitz 1998). FGF activity and specificity are further regulated by heparan sulfate oligosaccharides, in the form of heparan sulfate proteoglycans. Heparin/Heparan sulfate, FGF, and an FGF receptor (FGFR) associate to form a trimolecular complex (Rapraeger et al. 1991; Yayon et al. 1991; Ornitz et al. 1992). Heparan chains, themselves, have unique tissue-specific modifi-

cations that are required for, and may actually regulate, functional ligand–receptor interactions (Rapraeger 1995; Guimond and Turnbull 1999; Ornitz 2000; Allen et al. 2001).

Mutations in FGF receptors in chondrodysplasia and craniosynostosis syndromes

The importance of FGF signaling in skeletal development was first revealed with the discovery that a point mutation in the transmembrane domain of FGFR3 is the etiology of Achondroplasia, the most common genetic form of dwarfism in humans (Fig. 2; Rousseau et al. 1994; Shiang et al. 1994). Since this discovery, the etiology of many other human skeletal dysplasias have been attributed to specific mutations in the genes encoding *FGF receptors 1, 2, and 3* (Muenke and Schell 1995; Wilkie

Figure 2. FGF receptor mutations in human chondrodysplasia and craniosynostosis syndromes. (Left, green) Mutations in FGF receptor 3. (ACH) Achondroplasia, (TD) thanatophoric dysplasia, (HCH) hypochondroplasia, (CDS) Crouzonodermoskeletal syndrome (Crouzon syndrome and acanthosis nigricans), (NSC) non-syndromic craniosynostosis. (Right, blue) Mutations in FGF receptor 2. (CS) Crouzon syndrome, (JWS) Jackson-Weiss syndrome, (PS) Pfeiffer syndrome, (AS) Apert syndrome, (BS) Beare-Stevenson cutis gyrata, (U) unclassified. (Right, red) (PS) A single mutation in FGF receptor 1 that causes Pfeiffer syndrome. The numbers represent the position of the mutant amino acid in the human coding sequence. Amino acids are abbreviated using standard single-letter abbreviations. Data source: Wilkie (1997), Naski and Ornitz (1998), and included references.

1997; Naski and Ornitz 1998; Cohen 2000c; Britto et al. 2001a; Ornitz 2001). These disorders can be broadly classified into two groups: (1) the dwarfing chondrodysplasia syndromes, which include hypochondroplasia (HCH) (Bellus et al. 1995), achondroplasia (ACH) (Rousseau et al. 1994; Shiang et al. 1994; Ikegawa et al. 1995; Superti-Furga et al. 1995), thanatophoric dysplasia (TD) (Rousseau et al. 1995, 1996; Tavormina et al. 1995a,b); and (2) the craniosynostosis syndromes, which include Apert syndrome (AS) (Wilkie et al. 1995b), Beare-Stevenson cutis gyrata (Przylepa et al. 1996), Crouzon syndrome (CS) (Jabs et al. 1994; Reardon et al. 1994; Gorry et al. 1995; Meyers et al. 1995, 1996; Oldridge et al. 1995; Park et al. 1995; Rutland et al. 1995; Schell et al. 1995; Steinberger et al. 1995; Wilkie et al. 1995a), Pfeiffer syndrome (PS) (Muenke et al. 1994; Lajeunie et al. 1995; Rutland et al. 1995; Schell et al. 1995; Meyers et al. 1996), Jackson-Weiss syndrome (JWS) (Jabs et al. 1994; Park et al. 1995; Meyers et al. 1996), and a non-syndromic craniosynostosis (NSC) (Bellus et al. 1996). All of these mutations are autosomal dominant and frequently arise sporadically.

Chondrodysplasia syndromes and mutations in FGFR3

ACH is characterized by reduced growth of long bones with proximal elements more severely affected than distal elements (referred to as rhizomelia). Additional phenotypic features include frontal bossing of the cranium, cranio-somatic disproportion, and frequently, compression of the foramen magnum associated with neurological sequela. HCH is characterized by mild short stature and shares some clinical features with ACH (Bellus et al. 1995). TD is characterized by a very severe skeletal dysplasia and is clinically similar to homozygous cases of ACH (Stanescu et al. 1990). Both TD and homozygous ACH are generally lethal during the first several months of life. In histologic sections, the growth plates of patients with ACH display narrowed zones of proliferating and hypertrophic chondrocytes with disorganization of the chondrocyte columns (Briner et al. 1991). The pathophysiology and genetics of these diseases have been extensively reviewed (Muenke and Schell 1995; Horton 1997; Vajo et al. 2000).

The phenotypes of HCH, ACH, and TD display progressively increasing clinical severity. Early goals of the analysis of mutations that cause these diseases were to establish a relationship between disease severity and the biochemical consequence of the mutations. Present work aims to understand the developmental function of FGFR3 and how FGFR3 signaling interacts with other signaling pathways. A long-term goal is to devise ways to ameliorate the phenotype in people carrying the ACH mutation.

The etiology of most cases of ACH is a glycine-to-arginine substitution in the transmembrane domain of FGFR3 (Fig. 2). This mutation activates FGFR3 in the absence of ligand. However, the mutant receptor is further activated in the presence of ligand (Naski et al. 1996; Webster and Donoghue 1996; Li et al. 1997). Two different substitution mutations account for most cases

of TD. An arginine-to-cysteine substitution in the extracellular domain (ECD) of FGFR3 (TD type I) results in ligand-insensitive constitutive activation and a lysine-to-glutamic acid substitution in the tyrosine kinase domain of FGFR3 (TD type II) results in ligand-sensitive hyperactivation of the receptor (Naski et al. 1996). Although the phenotypes of ACH and TD are related, the mechanisms by which these mutations activate FGFR3 are diverse. The transmembrane domain mutation may act by uncoupling ligand-mediated receptor activation from receptor internalization and degradation, leading to increased levels and consequently increased signaling of the receptor (Monson-Oman et al. 2000). The extracellular arginine-to-cysteine substitution in TD leads to the formation of disulfide-linked dimers, which result in constitutive activation of FGFR3 (Naski et al. 1996). In contrast, the intracellular lysine-to-glutamic acid substitution is thought to stabilize a noninhibitory conformation of the kinase regulatory loop (Mohammadi et al. 1996). In summary, the degree of activation of FGFR3 correlates well with the severity of the chondrodysplasia. This relationship provides the first evidence for negative regulation of chondrogenesis by FGFR3. This genotype-phenotype correlation is supported by several mouse models harboring activating mutations in FGFR3 (Table 1; Naski et al. 1998; Chen et al. 1999, 2001; Li et al. 1999; Wang et al. 1999; Segev et al. 2000; Iwata et al. 2001).

FGF receptor mutations induce craniosynostosis syndromes

Craniosynostosis is characterized by premature fusion of the cranial sutures. Associated phenotypes in some of the craniosynostosis syndromes also include malformations in the appendicular skeleton and nonskeletal phenotypes such as mental retardation. The histological analysis of fused cranial sutures in human craniosynostosis revealed normal mesenchymal cell proliferation but increased bone formation at the sites of primary ossification. This results from increased osteoblast maturation rather than an alteration in osteoblast number (De Pollak et al. 1996; Lomri et al. 1998). Mutations in *Fgfr1*, *Fgfr2*, and *Fgfr3* have been associated with craniosynostosis syndromes. However, the majority of craniosynostosis syndromes are associated with mutations in *Fgfr2* (Fig. 2; Muenke and Schell 1995; Park et al. 1995; Malcolm and Reardon 1996; Webster and Donoghue 1997; Wilkie 1997; Burke et al. 1998; Naski and Ornitz 1998; Lajeunie et al. 1999; Ornitz 2001). The pathophysiology and genetics of craniosynostosis syndromes have been recently reviewed (Wilkie 1997, 2000; Cohen 2000b; Britto et al. 2001a; Wilkie and Morriss-Kay 2001). Most of the mutations are missense, or small in-frame insertions or deletions that affect the highly conserved extracellular FGFR ligand-binding domain. However, some recently described mutations involve the intracellular tyrosine kinase domain of FGFR2 and presumably function to activate downstream signaling pathways (Kan et al. 2002).

Most mutations in the *Fgfr* gene family are dominant

Table 1. Mouse models for FGF signaling in skeletal development

Mouse model	Method/mechanism	Phenotype	Reference
Ectopic FGF2 expression	PGK promoter transgenic expression	Enlarged occipital bones, skeletal dwarfism	Coffin et al. 1995
Ectopic FGF2 expression	Adenoviral expression in suture	Coronal suture synostosis	Greenwald et al. 2001
Ectopic FGF9 expression	Type II collagen promoter transgenic expression	Achondroplasia-like dwarfism	Garofalo et al. 1999
Increased FGF3/FGF4 expression	Retrovirus insertion	Crouzon-like dysmorphology	Carlton et al. 1998
FGF2-deficient mice	Knockout mutation	Inhibition of bone formation/bone mass	Montero et al. 2000
FGF18-deficient mice	Knockout mutation	Delayed suture closure, expanded growth plate	Liu et al. 2002; Ohbayashi et al. 2002
Dominant-negative FGFR1	Adenoviral expression in suture	Inhibition of calvarial suture fusion	Greenwald et al. 2001
FGFR3-deficient mice	Knockout mutation	Skeletal overgrowth	Colvin et al. 1996; Deng et al. 1996
Gain of function, FGFR2c	Knockout of exon 9(IIIc), aberrant alternative splicing	Coronal synostosis	Hajihosseini et al. 2001; Yu and Ornitz 2001
P250R mutation, FGFR1	Knockin mutation	Craniosynostosis	Zhou et al. 2000
K644M mutation, FGFR3	Knockin mutation	Severe dwarfism	Iwata et al. 2001
S365C mutation, FGFR3	Knockin mutation	Severe dwarfism	Chen et al. 2001
K644E mutation, FGFR3	Knockin mutation	Achondroplasia-like dwarfism	Li et al. 1999
K644E mutation, FGFR3	Knockin mutation	Thanatophoric dysplasia-like dwarfism	Iwata et al. 2000
G380R mutation, FGFR3	Type II collagen or <i>Fgfr3</i> promoter transgenic expression, Knockin mutation	Achondroplasia-like dwarfism	Naski et al. 1998; Wang et al. 1999; Segev et al. 2000
G369C mutation, FGFR3	Knockin mutation	Achondroplasia-like dwarfism	Chen et al. 1999

and are thought to be gain-of-function mutations (Naski and Ornitz 1998; Cohen 2000c; Ornitz 2001; Wilkie and Morriss-Kay 2001). Several of the mutations in *Fgfr1* and *Fgfr2* in CS, PS, and JWS constitutively activate the receptor by stabilizing intermolecular disulfide bonds, causing ligand-independent dimerization and signaling (Neilson and Friesel 1995; Wilkie et al. 1995a; Galvin et al. 1996; Robertson et al. 1998). Other mutations are thought to prolong the duration of receptor signaling or alter ligand-binding specificity (Anderson et al. 1998; Mansukhani et al. 2000; Plotnikov et al. 2000; Yu et al. 2000; Ibrahimi et al. 2001). For example, one of the CS mutations in *Fgfr2* results in ligand-independent activation and dramatically decreased ligand binding (Mangasarian et al. 1997). However, the mutant receptor in AS has lost ligand-binding specificity and thus can be activated by inappropriate ligands (Plotnikov et al. 2000; Yu et al. 2000; Ibrahimi et al. 2001; Yu and Ornitz 2001). A mutation in FGFR3 has also been associated with a Crouzon-like phenotype and associated dermal thickening and hyperpigmentation (Crouzon syndrome with acanthosis nigricans). This syndrome is now referred to as Crouzonodermoskeletal syndrome (CDS) (Cohen 2000c).

The importance of FGF signaling in cranial bone development is further supported by mice harboring activating mutations in FGF signaling pathways (Table 1). Mice overexpressing FGF2 develop enlarged occipital bones, which are formed in part by intramembranous ossification (Coffin et al. 1995). Increased expression of

FGF3 and FGF4, induced by retroviral insertion, results in a phenotype that resembles CS (Carlton et al. 1998). Additionally, gain-of-function mutations in FGFR1 and FGFR2 in mice affect calvarial development. The P250R mutation in FGFR1 (orthologous to the P252R substitution associated with PS in humans) causes premature fusion of calvarial sutures (Zhou et al. 2000). In addition, a dominant mutation that affects alternative splicing in *Fgfr2* causes coronal synostosis in mice (Hajihosseini et al. 2001; Yu and Ornitz 2001). In contrast, loss-of-function mutations in *Fgfrs* have been less informative. Embryos lacking FGFR1 or FGFR2 die prior to skeletal development (Deng et al. 1994; Arman et al. 1999), and mice lacking FGFR3 do not have obvious defects in calvarial bones (Colvin et al. 1996; Deng et al. 1996). However, a secreted soluble FGFR2 ECD can inhibit FGF signaling and causes skull abnormalities in mice that resemble those induced by *Fgfr* mutations in humans (Celli et al. 1998). Of the FGFs thus far targeted in mice, only mice lacking FGF18 have revealed a phenotype in calvarial development. *Fgf18* null mice have delayed calvarial ossification, indicating a requirement for FGF18 in intramembranous bone formation (Liu et al. 2002; Ohbayashi et al. 2002).

FGF signaling in the developing limb bud

Fibroblast growth factors are involved in the earliest stages of limb development and in the formation of skel-

etal elements within the developing limb. The expression patterns and function of FGFs in early limb development have been extensively reviewed (Martin 1998). Briefly, in the developing limb bud, the epithelial splice form of FGF receptor 2 (FGFR2b) is expressed in ectoderm, and the mesenchymal splice form of FGF receptor 1 (FGFR1c) is expressed in limb mesenchyme (Fig. 3A). An early step in the initiation of the limb bud involves signaling from mesenchymally expressed FGF10 to FGFR2b to form the apical ectodermal ridge. FGF8 is subsequently expressed in the apical ectodermal ridge and is thought to signal back to FGFR1c in limb mesoderm (Fig. 3A,B). This pattern of reciprocal signaling is one of several essential events required for outgrowth and patterning of the limb.

The mesenchymal condensation

FGF receptor expression

The mesenchymal condensation is the first morphologic event leading to bone formation (Hall 1987; Hall and Miyake 1992). *Fgfr2* expression is first observed in mesenchyme as mesenchymal cells begin to coalesce in the central core of the developing limb (Fig. 3A). At the condensation stage of limb development, *Fgfr1* expression persists in limb mesenchyme and in mesenchymal cells in the periphery of the condensation, whereas *Fgfr2* expression can be observed in the morphologically distinct mesenchymal condensations but not in the surrounding loose connective tissue (Fig. 3A). These patterns of expression have been observed in chicken, mouse, and hu-

Figure 3. *Fgf* and *Fgf receptor* gene expression in developing endochondral and intramembranous bone. (A) *Fgf receptor* gene expression. *Fgfr1* is expressed in limb mesenchyme (M) and in the periphery of the mesenchymal condensation (pink). *Fgfr2* is first expressed in condensing mesenchyme (purple). *Fgfr3* expression is initiated as chondrocytes differentiate and proliferate (green). *Fgfr1* expression is present as chondrocytes hypertrophy (red), and *Fgfr2* expression is prominent in osteoblasts in the ossification center (purple). Both *Fgfr1* and *Fgfr2* appear to be coexpressed in the perichondrium (pink). (B) *Fgf* gene expression. At the limb bud stage, *Fgf10* is expressed in distal mesenchyme (M) (yellow) and *Fgf8* is expressed in the overlying apical ectodermal ridge (AER) (pink). *Fgf2* and *Fgf9* expression is observed in the developing condensation (blue), and *Fgf18* expression is observed in the perichondrium and presumptive joint positions (green). *Fgf7* is expressed in loose mesenchyme and perichondrium surrounding the mesenchymal condensation (tan). (C) (Right) *Fgf* expression. In developing cranial bones, *Fgf2*, *Fgf9*, and *Fgf18* (blue) are expressed in mesenchymal cells in the suture separating the two osteogenic fronts. *Fgf18* also is expressed in cells lining the endosteal and periosteal surface of calvarial bones. (Left) *Fgf receptor* expression. *Fgfr1* (red) and *Fgfr3* (green dots) are found in the dura mater and periosteum, whereas *Fgfr1* (red dots) and *Fgfr2* (purple) are expressed in osteoprogenitor cells at the osteogenic front separating the suture.

man limb development (Orr-Urtreger et al. 1991; Peters et al. 1992; Szebenyi et al. 1995; Delezoide et al. 1998). Later in skeletal development, *Fgfr1* and *Fgfr2* expression persists in the perichondrium and periosteum in patterns that suggest expression in the osteoblast lineage (Delezoide et al. 1998). As chondrogenesis begins in the center of the condensation, *Fgfr3* expression is first observed (Peters et al. 1993).

FGF signaling in condensing mesenchyme

The physiologic ligands that activate FGFRs in the mesenchymal condensation have been difficult to identify. At the condensation stage, *Fgf9* is expressed within condensing mesenchyme (Fig. 3B; Colvin et al. 1999). However, in the absence of FGF9 there are no apparent defects in skeletal development (Colvin et al. 2001a,b). Similarly, *Fgf2*, *Fgf5*, *Fgf6*, and *Fgf7* are expressed in loose mesenchyme outside the condensation (Haub and Goldfarb 1991; deLapeyriere et al. 1993; Mason et al. 1994; Finch et al. 1995; Savage and Fallon 1995). However, mice lacking these FGFs have no apparent defects in skeletal development (Hebert et al. 1994; Guo et al. 1996; Fiore et al. 1997). It is possible that a combination of these and other FGFs may constitute the complete FGF signal to the developing condensation.

The role of FGF signaling in condensing mesenchyme is poorly understood. In primary chondrocytes and in undifferentiated mesenchymal cells, FGF signaling pathways induce the expression of SOX9, an essential transcription factor for chondrocyte differentiation (Murakami et al. 2000). Additionally, FGFR3 signaling may enhance chondrocyte proliferation in the mesenchymal condensation, even though it is well established that this receptor negatively regulates chondrogenesis during late embryonic and postnatal development (Iwata et al. 2000, 2001). Defects in signaling in the mesenchymal condensation could lead to skeletal abnormalities such as the bony syndactyly resulting from mutations in FGFR2 in Apert syndrome. The Apert mutations result in loss of ligand binding specificity, allowing inappropriate activation of FGFR2 in the mesenchymal condensation by mesenchymally expressed ligands such as FGF7 and inappropriate activation of FGFR2b by ligands such as FGF2, FGF6, and FGF9 (Yu et al. 2000; Yu and Ornitz 2001).

Endochondral ossification

Expression of FGFs and FGF receptors in endochondral bone

Shortly after formation of a mesenchymal condensation, chondrogenesis ensues, and *Fgfr3* expression is initiated in chondrocytes in the differentiated core of the mesenchymal condensation (Fig. 3A). At this stage, overlap in expression may exist with *Fgfr2*. As the epiphyseal growth plate is formed, *Fgfr1* expression is initiated as chondrocytes further differentiate and hypertrophy. In-

terestingly, *Fgfr1* and *Fgfr3* have very distinct domains of expression with little overlap; *Fgfr3* is expressed in proliferating chondrocytes, whereas *Fgfr1* is expressed in prehypertrophic and hypertrophic chondrocytes (Peters et al. 1992, 1993; Deng et al. 1996). This juxtaposition of FGFR1 and FGFR3 expression domains suggests unique functions. Expression of *Fgfr3* in the reserve and proliferating zone suggests a direct role for FGFR3 in regulating chondrocyte proliferation and possibly differentiation (Peters et al. 1993; Delezoide et al. 1998; Naski et al. 1998). In contrast, the expression of *Fgfr1* in hypertrophic chondrocytes (Peters et al. 1992; Delezoide et al. 1998) suggests a role for FGFR1 in survival of the hypertrophic chondrocyte, in regulating a feedback signal to control the rate of differentiation, in regulating the production of the unique extracellular matrix products of these cells, or in signaling their eventual apoptotic death. Interestingly, examination of FGFR3 protein in rib cartilage shows the presence of large amounts of cleaved FGFR3 ECD within the extracellular matrix of hypertrophic chondrocytes, suggesting that proteolytic processing could regulate the activity of FGFR3 and that the FGFR3 ECD could bind ligand and thus modify FGFR1 signaling in hypertrophic chondrocytes (Pandit et al. 2002).

Several FGFs are expressed in developing endochondral bone (Fig. 3B). Historically, FGF2 was the first FGF ligand to be isolated from growth plate chondrocytes (Sullivan and Klagsbrun 1985). Subsequently, *Fgf2* expression has also been observed in periosteal cells and in osteoblasts (Hurley et al. 1994, 1999; Sabbieti et al. 1999). Targeted deletion of FGF2 causes a relatively subtle defect in osteoblastogenesis, leading to decreased bone growth and bone density. However, no defects in chondrogenesis were observed (Montero et al. 2000). *Fgf9* is also expressed in chondrocytes (Colvin et al. 1999; Garofalo et al. 1999). However, the skeleton of *Fgf9*^{-/-} mice is apparently normal at birth when these mice die of other causes (Colvin et al. 2001a,b).

In the perichondrium, expression of *Fgf7*, *Fgf8*, *Fgf17*, and *Fgf18* has been observed (Mason et al. 1994; Finch et al. 1995; Xu et al. 1999; Liu et al. 2002; Ohbayashi et al. 2002), suggesting a possible paracrine signal to the growth plate. Recent genetic studies have identified a defect in chondrogenesis and osteogenesis in mice lacking FGF18 (Liu et al. 2002; Ohbayashi et al. 2002). Mice lacking FGF7, FGF8, and FGF17 have apparently normal chondrogenesis, or in the case of FGF8 die prior to skeletal development (Guo et al. 1996; Meyers et al. 1998; Xu et al. 2000). Issues of functional redundancy among these and other FGFs will need to be addressed in the future.

Signaling pathways that regulate endochondral bone development

The growth plate is a developmental center that integrates many diverse signals to coordinate the complex patterning and growth of the skeleton. Each growth plate must appropriately respond to positional cues and endo-

ocrine and local signals to coordinate the formation of each unique skeletal element. Local signaling pathways that are known to coordinate endochondral bone growth include (but are not limited to) the parathyroid hormone related peptide (PTHrP), Indian hedgehog (IHH), bone morphogenic proteins (BMPs), and FGFs. Current research aims to understand the function of these and other signaling pathways and how they interact with each other to coordinate bone growth.

PTHrP and IHH form a feedback loop that regulates the rate of chondrocyte differentiation (Fig. 4A). *Ihh* is expressed in distal prehypertrophic and proximal hypertrophic chondrocytes (Bitgood and McMahon 1995), whereas *Pthrp* is expressed in perichondrial and periarticular chondrocytes (Amizuka et al. 1994; Karaplis et al. 1994; Lee et al. 1995). The PTH/PTHrP receptor (PPR) is expressed in distal proliferating and proximal prehypertrophic chondrocytes proximal to *Ihh*, positioned to

regulate the rate of chondrocyte differentiation. The IHH receptor, Patched (PTC), and associated signaling molecules (Smoothed, Gli1, Gli3), are located throughout the growth plate and perichondrium (Iwasaki et al. 1997). IHH induces the expression of PTHrP (Vortkamp et al. 1996; Chung et al. 2001; Minina et al. 2001), and in mice lacking IHH, chondrocytes prematurely differentiate, resulting in a short-limbed dwarfism (St-Jacques et al. 1999). A similar phenotype is observed in mice with a targeted disruption of *Pthrp* or the *Ppr* (Karaplis et al. 1994; Lanske et al. 1996). The net effect of this feedback loop is to regulate the number of chondrocytes undergoing hypertrophic differentiation (Kronenberg and Chung 2001). IHH also has been shown to stimulate chondrocyte proliferation independently of PTHrP signaling (St-Jacques et al. 1999; Karp et al. 2000; Chung et al. 2001).

The IHH/PTHrP signaling loop also interacts with members of the bone morphogenic protein (BMP) family.

Figure 4. Regulatory pathways in endochondral and intramembranous bone. (A) Chondrocytes progress through reserve (R), proliferating (P), prehypertrophic (PH), and hypertrophic (H) stages. Expression patterns and interactions of molecules that regulate these events are color coded and diagramed. (IHH) Indian hedgehog; (PTC) patched; (SMO) smoothened; (BMPs) bone morphogenic proteins; (PTHrP) parathyroid hormone related peptide; (PPR) PTHrP receptor. (B) During intramembranous bone development, the proliferation of mesenchymal cells is followed by their commitment to become osteoprogenitor cells. Osteoprogenitor cells differentiate into pre-osteoblasts and then into bone matrix-forming mature osteoblasts. The stimulatory effects (arrow) of FGFs, FGFRs, and BMPs on cell proliferation (1), differentiation (2,3), osteogenesis (4,5) and apoptosis (6,7) during this progressive differentiation pathway are shown.

Unlike PTHrP, BMP signaling promotes the proliferation of chondrocytes and delays maturation of differentiated hypertrophic chondrocytes, resulting in an enlarged skeleton (Fig. 4A; Duprez et al. 1996; Zou et al. 1997; Minina et al. 2001). This effect of BMP occurs independently of IHH and PTHrP (Minina et al. 2001). A further consequence of BMP signaling is to increase the domain of *Ihh* expression (Kawakami et al. 1996; Pathi et al. 1999; Capdevila and Belmonte 2001; Minina et al. 2001). IHH signaling also interacts with the BMP pathway by up-regulating expression of *Bmp2* and *Bmp4* in the growth plate (Pathi et al. 1999; Minina et al. 2001). The net effect of this signaling loop is to promote chondrogenesis.

FGF signaling pathways in the growth plate

Analysis of both gain-of-function and loss-of-function mutations in FGFR3 at late gestational and postnatal stages of mouse development shows that the net consequence of signaling through this receptor is to limit chondrocyte proliferation and differentiation (Fig. 4A; Naski and Ornitz 1998; Ornitz 2001). This effect is mediated in part by direct signaling in chondrocytes (Henderson et al. 2000; Rozenblatt-Rosen et al. 2002) and in part indirectly, by regulating the expression of the IHH/PTHrP/BMP signaling pathways. Mice harboring an activating mutation in FGFR3 have decreased expression of *Ihh*, *Ptc*, and *Bmp4* (Naski et al. 1998; Li et al. 1999; Chen et al. 2001), whereas in mice lacking FGFR3, *Ihh*, *Ptc*, and *Bmp4* expression are up-regulated (Naski et al. 1998; data not shown). The overall function of FGFR3 is consistent with a direct action of FGFR3 on proliferating chondrocytes (see below) and an indirect consequence of modulating Hedgehog and BMP signaling (Fig. 4A).

The ligands that signal to FGFR3 during endochondral ossification have been elusive. However, recent data show that growth plate histology of mice lacking FGF18 is similar to that of mice lacking FGFR3. This includes the up-regulation of *Ihh* and *Ptc* expression and increased chondrocyte proliferation. These similarities provide strong evidence for a ligand–receptor relationship between FGF18 and FGFR3 (Liu et al. 2002; Ohbayashi et al. 2002). Furthermore, in vitro, FGF18 can activate FGFR3c (Xu et al. 2000) and stimulate the proliferation of cultured articular chondrocytes (Ellsworth et al. 2002). FGF18 is most closely related to FGF8 and FGF17 (Ornitz and Itoh 2001) and may not be the only FGF ligand functioning in developing bone. There is some evidence for expression of FGF8 and FGF17 in developing bone (Xu et al. 1999), suggesting that there may be additional redundancy among these three ligands.

Chondrogenesis and osteogenesis must be tightly coordinated to correctly form and generate a biomechanically robust structure. Regulation of endochondral ossification by FGFs, IHH, PTHrP, and BMPs involves signaling between different populations of chondrocytes and between chondrocytes and the perichondrium. Several studies have shown that the perichondrium elaborates a signal that negatively regulates both chondrocyte proliferation and differentiation (Long and Linsenmayer

1998; Haaijman et al. 1999; Alvarez et al. 2001). The expression pattern of *Fgf18* and the phenotype of *Fgf18* null mice make FGF18 a good candidate for this signal. However, PTHrP and BMPs are also expressed in the perichondrium and may also contribute to this signal. In the reverse direction, IHH is the only factor identified thus far that signals from chondrocytes to the perichondrium (Karaplis and Goltzman 2000; Chung et al. 2001).

Mice lacking *Fgf18* have a more severe phenotype than mice lacking *Fgfr3* (Liu et al. 2002). Unlike in *Fgfr3*^{−/−} mice, *Fgf18*^{−/−} mice show delayed ossification in the long bone and decreased growth of cranial bones. These observations suggest that FGF18 may signal to FGFR1 in hypertrophic chondrocytes and to FGFR1 or FGFR2 in the perichondrium and periosteum. Like IHH and BMPs, FGF18 may also serve to coordinate the development of these closely associated compartments. A prediction of this model is that the expression of *Fgf18* in the perichondrium must be tightly regulated by other factors. Interestingly, TGF- β requires the presence of the perichondrium to inhibit chondrocyte proliferation and differentiation (Alvarez et al. 2001). Therefore, TGF- β , as well as IHH and BMPs, could act by regulating *Fgf18* expression in the perichondrium.

Response of the chondrocyte to FGF signaling

Inhibition of chondrocyte proliferation could result from either unique signaling properties of FGFR3 or a unique response of the proliferating chondrocyte to an FGFR signal. FGFR1 and FGFR3 have different signaling properties in some cell types in vitro (Wang et al. 1994; Lin et al. 1996; Naski et al. 1996). These differences may be attributable to differences in the strength of the tyrosine kinase signal but not to the specific signaling pathway activated (Raffioni et al. 1999). Consistent with this, both receptor kinase domains appear to have similar activities when expressed in proliferating chondrocytes in vivo (Wang et al. 2001). This observation supports the hypothesis that the proliferating chondrocyte itself is uniquely responsive to an FGFR signal. Interestingly, during embryonic development, constitutive FGFR3 activation enhances chondrocyte proliferation (Iwata et al. 2000, 2001). Taken together, these data suggest that the proliferating growth plate chondrocyte is a uniquely differentiated type of chondrocyte that acquires specific responsiveness to FGF signals during late embryonic and postnatal skeletal development.

This unique response of the chondrocyte may result from both indirect signals mediated by IHH and direct signals from both IHH and FGFR3. Expression of constitutively activating mutations in FGFR3 or treatment of cells with FGF can induce nuclear translocation of STAT1 and STAT3 and induce the expression of the cell cycle inhibitor p21(WAF1/CIP1) (Su et al. 1997; Sahni et al. 1999; Hart et al. 2000). Furthermore, chondrocytes isolated from patients with Thanatophoric dysplasia, showed nuclear STAT1, increased *Bax* expression, decreased *Bcl2* expression, and an increase in the number of apoptotic chondrocytes, suggesting that signaling

through STAT1 may also regulate cell death (Legeai-Mallet et al. 1998).

In vivo, the dwarfism phenotype observed in mice expressing activating mutations in FGFR3 correlated with the activation of STAT proteins and up-regulation of cell cycle inhibitors (p16, p18, and p19; Chen et al. 1999; Li et al. 1999). Interestingly, in primary chondrocytes derived from mice lacking STAT1, FGF signaling failed to induce chondrocyte growth inhibition (Sahni et al. 1999). Additionally, mating FGF2-expressing transgenic mice into a *Stat1* null background corrected the chondrodysplasia phenotype characteristic of this transgenic line (Sahni et al. 2001). These data support a model in which STAT1 mediates the growth inhibition by FGFR3.

FGF functions in intramembranous bone formation

FGF and FGFR signaling in intramembranous bone formation

The expression of FGFs and FGFRs is temporally and spatially regulated during craniofacial development. During intramembranous bone formation, *Fgf2*, *Fgf4*, and *Fgf9* are expressed in sutural mesenchyme in early craniofacial skeletogenesis, suggesting that they may be involved in regulating calvarial osteogenesis (Kim et al. 1998; Mehrara et al. 1998; Rice et al. 2000; Britto et al. 2001b). *Fgf18* (Liu et al. 2002; Ohbayashi et al. 2002) and *Fgf20* (Hajihosseini and Heath 2002) are also expressed in developing calvarial bones, and mice lacking *Fgf18* have defects in calvarial development (Liu et al. 2002; Ohbayashi et al. 2002). *Fgf18* is first detected in calvarial mesenchymal cells and later in development is expressed in osteogenic mesenchyme and in differentiated osteoblasts on the endosteal and periosteal surface of cranial bones (Fig. 3C; Liu et al. 2002; Ohbayashi et al. 2002).

Fgfr1 is expressed in the calvarial mesenchyme and later in osteoblasts, whereas *Fgfr2* is expressed at sites of ossification in differentiating osteoblasts (Hughes 1997; Britto et al. 1998, 2001b; Delezoide et al. 1998; Marie et al. 2000; Ohbayashi et al. 2002). *Fgfr3* is not found in calvarial mesenchymal cells or periosteal cells but is detected at low levels in sutural osteogenic fronts at late stages of development (Delezoide et al. 1998; Molteni et al. 1999; Marie et al. 2000; Rice et al. 2000). However, mice lacking *Fgfr3* do not have defects in calvarial development (Colvin et al. 1996; Deng et al. 1996). It is therefore likely that intramembranous bone formation is controlled primarily by FGFR1 and FGFR2.

Transcriptional mechanisms regulating calvarial bone formation and suture development

Several transcription factors control osteogenic differentiation at the level of the suture. The early commitment of mesenchymal stem cells into osteoblasts requires expression of CBFA1/RUNX2, a transcription factor that regulates several osteoblast genes including type I colla-

gen, bone sialoprotein, osteopontin, and osteocalcin (Ducy et al. 1997). CBFA1 is essential for intramembranous bone formation, and haploinsufficiency at the *Cbfa1* locus leads to delayed membranous ossification in mice and humans (Komori et al. 1997; Lee et al. 1997; Mundlos et al. 1997). Other transcription factors are also important for intramembranous bone formation. MSX1 and MSX2 are homeobox-containing transcription factors that are associated with the differentiation of neural crest-derived intramembranous calvarial bones. *Msx2* is expressed in the mesenchyme and acts by inhibiting calvarial osteoblast differentiation (Towler et al. 1994; Dodig et al. 1999). MSX2 overexpression in mice and mutations in *Msx2* in humans induce precocious bone formation and craniosynostosis by increasing the number of osteoprogenitor cells (Jabs et al. 1993; Liu et al. 1995, 1999). In contrast, haploinsufficiency of *Msx2* decreases cell proliferation, delays suture closure, and causes defects in skull ossification in both humans and mice (Dodig et al. 1999; Satokata et al. 2000; Wilkie et al. 2000). Inactivation of DLX5, a transcription factor that regulates osteocalcin expression (Newberry et al. 1998), induces delayed ossification of membranous bone in mice (Acampora et al. 1999). Haploinsufficiency of *Twist*, a basic helix-loop-helix transcription factor, results in premature cranial ossification (el Ghouzzi et al. 1997; Howard et al. 1997). *Twist* is expressed in sutural mesenchyme and affects osteoblast gene expression and apoptosis in calvarial osteoblasts (Yousfi et al. 2001, 2002). Conversely, delayed suture closure is associated with trisomy at the human *Twist* locus (Stankiewicz et al. 2001). It is likely that these factors interact to control cranial suture ossification.

FGF signaling affects the expression and activity of several transcription factors that are required for calvarial osteogenesis. In rat or mouse calvarial cells, FGF2 activates osteocalcin transcription. This activity is inhibited by the transcription factor MSX2 and is activated by DLX5 (Newberry et al. 1996, 1998, 1999). Similarly, FGF4 can stimulate *Msx1* gene expression and cell proliferation (Kim et al. 1998), and FGF2 can up-regulate *Twist* expression in mouse calvarial mesenchyme (Rice et al. 2000). *Twist* heterozygous mice show altered FGFR protein expression (Rice et al. 2000), suggesting that TWIST acts upstream of FGF signaling pathways. Additionally, *Twist* could be a potential transcriptional regulator that mediates the negative effect of FGF2 on type I collagen expression in calvarial cells (Fang et al. 2001). Thus, FGF/FGFR, MSX, and TWIST interact to control cranial suture development in a coordinated manner.

Biological functions of FGFs in cranial bone formation

The biological effects of FGFs on osteogenic cells depend on their stage of differentiation. In vitro studies show that FGF1, FGF2, FGF4, or FGF18 can potentiate growth of fetal or neonatal calvarial osteoblasts (Canalis et al. 1988; Tang et al. 1996; Hurley et al. 2001; Shimoaka et al. 2001) but not mature osteoblasts (Debiais et al. 1998; Mansukhani et al. 2000). In vivo, FGF2 increases the

number of osteogenic cells and promotes calvarial osteogenesis (Mundy et al. 1999). In contrast, calvarial osteogenesis is decreased in mice lacking FGF2, or following inhibition of endogenous FGF2 activity (Montero et al. 2000; Moore et al. 2002). These data support a role for endogenous FGF2 as an autocrine mitogenic factor in calvaria.

FGF2 production by calvarial osteoblasts is up-regulated by FGF2 itself, and by parathyroid hormone, PGE₂, and TGF- β (Hurley et al. 2001). Thus, the balance between high and low levels of endogenous FGF2 may constitute a mechanism to control proliferation and ensure normal cranial vault morphogenesis (Moore et al. 2002). In addition to FGF2, FGF18 appears to be important for calvarial development. Recent analysis of *Fgf18* null embryos revealed a transient decrease in the proliferation of osteogenic mesenchymal cells associated with delayed suture closure (Ohbayashi et al. 2002). Therefore, at least two FGFs control osteogenic cell proliferation during calvarial development.

FGFs also regulate calvarial cell differentiation. In vitro, FGFs inhibit type I collagen expression and bone nodule formation of rat calvarial cells (Tang et al. 1996; Hurley et al. 2001). However, prolonged treatment with FGF2 increases calvarial osteoblast differentiation (Debiais et al. 1998). FGF2 promotes osteocalcin transcription in rodent and human calvarial osteoblasts (Schedlich et al. 1994; Boudreaux and Towler 1996; Newberry et al. 1996, 1998; Debiais et al. 1998). This effect, together with the reported increase in sodium-dependent phosphate transport (Suzuki et al. 2000), may contribute to the regulation of intramembranous calcification. Recent in vitro data indicate that FGF18 can act like FGF2 to regulate calvarial osteoblast differentiation in vitro (Shimoaka et al. 2001). Consistent with this, decreased terminal differentiation of osteoblasts was observed in *Fgf18* null mice, which may contribute to delayed suture ossification (Ohbayashi et al. 2002). Thus, FGF18 is required for both the promotion of osteogenic mesenchymal cell proliferation and osteoblast differentiation in developing calvarial bones (Fig. 4B).

In addition to regulating rates of proliferation and differentiation, FGF signaling may also regulate cell death in the cranial suture, a critical factor for determining suture patency. Perturbations in the number of apoptotic cells can lead to either premature or delayed suture closure (Rice et al. 1999). The effects of FGF signaling on osteoblast apoptosis are dependent on the developmental stage. FGF2 reduces apoptosis in cultured calvarial cells (Hill et al. 1997) but stimulates apoptosis in the developing coronal suture (Mathijssen et al. 2001). In transgenic mice overexpressing FGF2, apoptosis is restricted to more differentiated calvarial osteoblasts at the osteogenic front (Mansukhani et al. 2000). These observations and studies on proliferation and differentiation show that FGFs can control the balance between undifferentiated and differentiated osteogenic cells by increasing the proliferation of immature cells and by promoting the differentiation and apoptosis of more mature osteoblasts in developing calvaria (Fig. 4B).

FGFs may also affect calvarial osteogenic cells by regulating endogenous factors such as insulin-like growth factors (IGFs) and their regulatory binding protein BP5 (Canalis and Gabbittas 1995; Hurley et al. 1995), as well as vascular endothelial growth factor (Saadeh et al. 2000), hepatocyte growth factor (Blanchaert et al. 1999), and TGF- β (Noda and Vogel 1989; Debiais et al. 1998). TGF- β 2 and TGF- β 3 are also secreted by the dura mater and regulate osteogenic suture cell proliferation and apoptosis (Cohen 1997; Opperman 2000). Both TGF- β 1 and FGF2 expression are up-regulated as cranial sutures fuse, suggesting a paracrine signal from dura to regulate suture closure (Most et al. 1998). Some BMPs are also expressed in the dura, sutural mesenchyme, and the osteogenic front (Opperman 2000). BMP signaling promotes the differentiation and apoptosis of calvarial osteoblasts (Hay et al. 1999, 2001; Yamaguchi et al. 2000) and may thus act in concert with FGFs to control calvarial growth and differentiation during intramembranous bone development (Fig. 4B; Opperman 2000; Marie et al. 2002).

Bone resorption by osteoclasts is required to maintain the shape of craniofacial bones during development. It is therefore significant that FGF2 can increase the formation of osteoclast-like cells (Hurley et al. 1998; Nakagawa et al. 1999) and activate mature osteoclasts (Kawaguchi et al. 2000) through FGFR1 (Chikazu et al. 2000). FGF18 also can promote osteoclast formation through RANKL (receptor activator of NF- κ B ligand) signaling (Shimoaka et al. 2001). In addition, FGF2 increases the expression of metalloproteinases, collagenases 1 and 3 (Varghese et al. 1995, 2000; Tang et al. 1996; Newberry et al. 1997), tissue inhibitors of metalloproteinases (TIMP) 1 and 3 (Varghese et al. 1995), and stromelysin-3 (which regulates collagenase activity in calvarial cells; Delaney and Canalis 1998). These mechanisms may control bone matrix degradation and remodeling by FGFs during calvarial expansion.

FGF signaling pathways in intramembranous bone formation

Multiple FGF-induced signaling pathways are involved in the control of the calvarial cell phenotype during intramembranous bone formation. FGFs activate ERK and p38 MAPK signaling pathways in osteoblasts (Hurley et al. 1996; Chaudhary and Avioli 1997, 2000; Kozawa et al. 1999; Tokuda et al. 2000; Shimoaka et al. 2001). FGF2 and FGF18 stimulate ERK2 phosphorylation, which promotes mitogenesis (Hurley et al. 1996; Chaudhary and Avioli 1997, 2000; Shimoaka et al. 2001) and down-regulates procollagen gene expression in calvarial osteoblasts (Chaudhary and Avioli 1997, 2000). The protein kinase C (PKC) pathway is involved in the control of sodium-dependent phosphate transport (Suzuki et al. 2000) and expression of N-cadherin in calvarial osteoblasts (Debiais et al. 2001). Mutations in *Fgfr2* that cause Apert syndrome induce constitutive activation of PKC in human calvarial osteoblasts (Fragale et al. 1999; Lomri et al. 2001). This signaling pathway is responsible for the increased differentiation and apoptosis in mutant osteo-

blasts (Lemonnier et al. 2000, 2001a). Whether *Fgfr* mutations induce alterations in other pathways in calvarial osteoblasts is at present unknown.

Control of cranial suture closure by FGF signaling

Several experiments indicate that FGF signaling enhances suture closure by regulating the progression of undifferentiated cells toward mature osteoblasts. Implantation of FGF beads over a suture accelerates suture closure at late developmental stages (Iseki et al. 1997; Kim et al. 1998; Greenwald et al. 2001; Mathijssen et al. 2001). However, at early developmental stages, FGF4 increases proliferation of undifferentiated mesenchymal cells and delays suture closure (Kim et al. 1998). FGF signaling was suggested to shift the cell proliferation/differentiation balance toward differentiation by down-regulating *Fgfr2* expression (Iseki et al. 1997; Kim et al. 1998; Mehrara et al. 1998; Most et al. 1998; Johnson et al. 2000). Accordingly, *Fgfr2* expression is down-regulated in osteoblast progenitor cells and osteoblasts at the osteogenic front in fused sutures in Apert (Bresnick and Schendel 1998; Lemonnier et al. 2000) and Crouzon syndrome patients (Bresnick and Schendel 1995). Negative autoregulation of *Fgfr2* also characterizes cranial development in Apert and Pfeiffer syndromes (Britto et al. 2001b). In mice, the down-regulation of *Fgfr2* induced by FGF2 application at the osteogenic front is associated with increased *Fgfr1* expression, which may enhance osteoblast differentiation (Iseki et al. 1999). Consistent with this hypothesis, expression of a dominant-negative FGFR1 gene inhibits suture fusion in rat calvaria (Greenwald et al. 2001). These data suggest that gradients of FGFR1 and FGFR2 may regulate the balance between proliferation and differentiation of osteogenic cells in the cranial suture.

Several cellular mechanisms may contribute to the premature suture closure induced by gain-of-function mutations in FGFRs. In nonosteoblastic cells, the expression of FGFR2 harboring a Crouzon mutation results in increased cell proliferation (Galvin et al. 1996). In murine calvarial cells, transfection of the *Fgfr2* S252W (Apert mutation) gene inhibits cell differentiation and increases proliferation (Mansukhani et al. 2000). In human osteoblasts, Apert syndrome mutations do not increase cell proliferation (Lomri et al. 1998; Fragale et al. 1999; Lemonnier et al. 2000) but alternatively, increase the expression of type 1 collagen, osteocalcin, and osteopontin, and enhance osteogenesis (Lomri et al. 1998; Lemonnier et al. 2000). This premature osteogenic cell differentiation induced by Apert *Fgfr2* mutations is associated with increased N-cadherin expression and cell-cell adhesion (Lemonnier et al. 2001b), which is reproduced by application of FGF2 (Debiais et al. 2001). The increased osteoblast differentiation and bone formation induced by activating mutations in *Fgfr2* is consistent with the phenotype of stenotic sutures in human nonsyndromic craniosynostosis (De Pollak et al. 1996; Shevde et al. 2001). The murine FGFR1 P250R mutation also increases expression of osteoblast differentiation genes

such as *Cbfa1*, bone sialoprotein, and osteocalcin (Zhou et al. 2000). Similarly, activation of FGFR3 by a G369C mutation also enhances osteoblast differentiation during endochondral bone formation (Chen et al. 1999). Therefore, most activating mutations in FGFRs appear to result in premature differentiation of osteogenic cells in the suture (Marie et al. 2000, 2002; Opperman 2000).

Increased apoptosis is another feature of craniosynostoses that is enhanced by mutations in *Fgfr2*. In murine or human osteoblasts, activating FGFR2 C342Y (Crouzon) or S252W (Apert) mutations promote apoptosis (Mansukhani et al. 2000; Lemonnier et al. 2001a). In human mutant osteoblasts, this is mediated by increased expression of *interleukin-1* and the pro-apoptotic proteins FAS and BAX (Lemonnier et al. 2001a). Thus, FGFR2 activation enhances apoptosis in calvarial osteoblasts following acceleration of terminal osteoblast maturation (Fig. 4B).

Conclusions and unresolved questions

Experimental and genetic evidence shows that FGFs and FGFRs are critical for the control of endochondral and intramembranous bone formation during development. FGF signals control the balance among skeletal cell growth, differentiation, and apoptosis. The identification of signaling molecules that act both upstream and downstream of FGFRs has led to a more comprehensive view of the mechanisms that control skeletal development and has provided a molecular basis for understanding the pathogenesis of chondrodysplasia and craniosynostosis syndromes.

Important unresolved issues include the identification of the pathways that are activated by FGF/FGFR signaling at different stages of skeletal development and how these pathways and molecules feed back to regulate FGF signaling. Thus far only 2 of the 22 known FGF ligands have been shown to be essential for skeletal development. The factors that regulate these FGFs and the identity and function of additional members of the FGF family that function in skeletogenesis remain to be discovered. Additional factors that regulate FGF activity, such as heparan sulfate proteoglycans that act as cofactors for FGF-FGFR interactions, may also have important roles in regulating bone growth. Diseases such as Simpson-Golabi-Behmel syndrome, in which increased skeletal growth occurs as a consequence of loss-of-function mutations in the *glypican-3* gene (DeBaun et al. 2001), could act by modulating the activity of either stimulatory or inhibitory FGF signaling pathways.

Several mouse models for chondrodysplasia and craniosynostosis syndromes have been made. These mice appear to phenocopy many aspects of their human disease counterparts. It will be important to exploit these mouse models to assess not only the developmental biology of the phenotype, but also genetic interactions and novel genes affected by altered FGFR activity in bone tissue. Similarly, loss-of-function mutations in FGFR3 have been informative, but analysis of loss-of-function mutations in FGFR1 and FGFR2 in skeletal development

will require conditional gene targeting or possibly splice form-specific mutations.

Acknowledgments

This work was supported by NIH grant HD39952, a gift from the Virginia Friedhofer Charitable Trust (D.M.O.), and by INSERM and the Ministère de la Recherche et de la Technologie (P.J.M.). We also thank D. Redmond for help with artwork.

References

- Acampora, D., Merlo, G.R., Paleari, L., Zerega, B., Postiglione, M.P., Mantero, S., Bober, E., Barbieri, O., Simeone, A., and Levi, G. 1999. Craniofacial, vestibular and bone defects in mice lacking the Distal-less-related gene *Dlx5*. *Development* **126**: 3795–3809.
- Allen, B.L., Filla, M.S., and Rapraeger, A.C. 2001. Role of heparan sulfate as a tissue-specific regulator of FGF-4 and FGF receptor recognition. *J. Cell Biol.* **155**: 845–858.
- Alvarez, J., Horton, J., Sohn, P., and Serra, R. 2001. The perichondrium plays an important role in mediating the effects of TGF- β 1 on endochondral bone formation. *Dev. Dyn.* **221**: 311–321.
- Amizuka, N., Warshawsky, H., Henderson, J.E., Goltzman, D., and Karaplis, A.C. 1994. Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. *J. Cell Biol.* **126**: 1611–1623.
- Anderson, J., Burns, H.D., Enriquez-Harris, P., Wilkie, A.O.M., and Heath, J.K. 1998. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. *Hum. Mol. Genet.* **7**: 1475–1483.
- Arman, E., Haffner-Krausz, R., Gorivodsky, M., and Lonai, P. 1999. *Fgfr2* is required for limb outgrowth and lung-branching morphogenesis. *Proc. Natl. Acad. Sci.* **96**: 11895–11899.
- Bellus, G.A., McIntosh, I., Smith, E.A., Aylesworth, A.S., Kaitila, I., Horton, W.A., Greenhaw, G.A., Hecht, J.T., and Francomano, C.A. 1995. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. *Nat. Genet.* **10**: 357–359.
- Bellus, G.A., Gaudenz, K., Zackai, E.H., Clarke, L.A., Szabo, J., Francomano, C.A., and Muenke, M. 1996. Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. *Nat. Genet.* **14**: 174–176.
- Bitgood, M.J. and McMahon, A.P. 1995. Hedgehog and Bmp genes are coexpressed at many diverse sites of cell–cell interaction in the mouse embryo. *Dev. Biol.* **172**: 126–138.
- Blanquaert, F., Delany, A.M., and Canalis, E. 1999. Fibroblast growth factor-2 induces hepatocyte growth factor/scatter factor expression in osteoblasts. *Endocrinology* **140**: 1069–1074.
- Boudreaux, J.M. and Towler, D.A. 1996. Synergistic induction of osteocalcin gene expression: Identification of a bipartite element conferring fibroblast growth factor 2 and cyclic AMP responsiveness in the rat osteocalcin promoter. *J. Biol. Chem.* **271**: 7508–7515.
- Bresnick, S. and Schendel, S. 1995. Crouzon's disease correlates with low fibroblastic growth factor receptor activity in stenosed cranial sutures. *J. Craniofac. Surg.* **6**: 245–248.
- . 1998. Apert's syndrome correlates with low fibroblast growth factor receptor activity in stenosed cranial sutures. *J. Craniofac. Surg.* **9**: 92–95.
- Briner, J., Giedion, A., and Spycher, M.A. 1991. Variation of quantitative and qualitative changes of enchondral ossification in heterozygous achondroplasia. *Pathol. Res. Pract.* **187**: 271–278.
- Britto, J.A., Chan, J.C., Evans, R.D., Hayward, R.D., Thorogood, P., and Jones, B.M. 1998. Fibroblast growth factor receptors are expressed in craniosynostotic sutures. *Plast. Reconstr. Surg.* **101**: 540–543.
- Britto, J.A., Evans, R.D., Hayward, R.D., and Jones, B.M. 2001a. From genotype to phenotype: The differential expression of FGF, FGFR, and TGF β genes characterizes human cranio-skeletal development and reflects clinical presentation in FGFR syndromes. *Plast. Reconstr. Surg.* **108**: 2026–2046.
- Britto, J.A., Moore, R.L., Evans, R.D., Hayward, R.D., and Jones, B.M. 2001b. Negative autoregulation of fibroblast growth factor receptor 2 expression characterizes cranial development in cases of Apert (P253R mutation) and Pfeiffer (C278F mutation) syndromes and suggesting a basis for differences in their cranial phenotypes. *J. Neurosurg.* **95**: 660–673.
- Burke, D., Wilkes, D., Blundell, T.L., and Malcolm, S. 1998. Fibroblast growth factor receptors: Lessons from the genes. *Trends Biochem. Sci.* **23**: 59–62.
- Canalis, E. and Gabbittas, B. 1995. Skeletal growth factors regulate the synthesis of insulin-like growth factor binding protein-5 in bone cell cultures. *J. Biol. Chem.* **270**: 10771–10776.
- Canalis, E., Centrella, M., and McCarthy, T. 1988. Effects of basic fibroblast growth factor on bone formation in vitro. *J. Clin. Invest.* **81**: 1572–1577.
- Capdevila, J. and Belmonte, J.C. 2001. Patterning mechanisms controlling vertebrate limb development. *Annu. Rev. Cell Dev. Biol.* **17**: 87–132.
- Caplan, A.I. and Pechak, D.G. 1987. The cellular and molecular embryology of bone formation. In *Bone and mineral research* (ed. W.A. Peck), pp. 117–183. Elsevier, New York.
- Carlton, M.B.L., Colledge, W.H., and Evans, M.J. 1998. Crouzon-like craniofacial dysmorphology in the mouse is caused by an insertional mutation at the *Fgf3/Fgf4* locus. *Dev. Dyn.* **212**: 242–249.
- Celli, G., LaRoche, W.J., Mackem, S., Sharp, R., and Merlino, G. 1998. Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. *EMBO J.* **17**: 1642–1655.
- Chaudhary, L.R. and Avioli, L.V. 1997. Activation of extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) by FGF-2 and PDGF-BB in normal human osteoblastic and bone marrow stromal cells: Differences in mobility and in-gel renaturation of ERK1 in human, rat, and mouse osteoblastic cells. *Biochem. Biophys. Res. Commun.* **238**: 134–139.
- . 2000. Extracellular-signal regulated kinase signaling pathway mediates downregulation of type I procollagen gene expression by FGF-2, PDGF-BB, and okadaic acid in osteoblastic cells. *J. Cell. Biochem.* **76**: 354–359.
- Chellaiah, A.T., McEwen, D.G., Werner, S., Xu, J., and Ornitz, D.M. 1994. Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1. *J. Biol. Chem.* **269**: 11620–11627.
- Chen, L., Adar, R., Yang, X., Monson, E.O., Li, C., Hauschka, P.V., Yayon, A., and Deng, C.X. 1999. Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. *J. Clin. Invest.* **104**: 1517–1525.
- Chen, L., Li, C., Qiao, W., Xu, X., and Deng, C. 2001. A Ser(365) $\rightarrow$ Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates *Ihh*/PTHrP signals and causes severe achondroplasia. *Hum. Mol. Genet.* **10**: 457–465.

- Chikazu, D., Hakeda, Y., Ogata, N., Nemoto, K., Itabashi, A., Takato, T., Kumegawa, M., Nakamura, K., and Kawaguchi, H. 2000. Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42/p44 MAP kinase. *J. Biol. Chem.* **275**: 31444–31450.
- Chung, U.I., Schipani, E., McMahon, A.P., and Kronenberg, H.M. 2001. Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development. *J. Clin. Invest.* **107**: 295–304.
- Coffin, J.D., Florkiewicz, R.Z., Neumann, J., Mort-Hopkins, T., Dorn II, G.W., Lightfoot, P., German, R., Howles, P.N., Kier, A., O'Toole, B.A., et al. 1995. Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. *Mol. Biol. Cell* **6**: 1861–1873.
- Cohen, Jr., M.M. 1997. Transforming growth factor β and fibroblast growth factors and their receptors: Role in sutural biology and craniosynostosis. *J. Bone. Miner. Res.* **12**: 322–330.
- . 2000a. Merging the old skeletal biology with the new. II. Molecular aspects of bone formation and bone growth. *J. Craniofac. Genet. Dev. Biol.* **20**: 94–106.
- . 2000b. Apert syndrome. In *Craniosynostosis, diagnosis, evaluation, and management* (eds. M.M. Cohen, Jr. and R.E. MacLean), pp. 316–353. Oxford University Press, New York.
- . 2000c. Fibroblast growth factor receptor mutations. In *Craniosynostosis, diagnosis, evaluation, and management* (eds. M.M. Cohen, Jr. and R.E. MacLean), pp. 77–94. Oxford University Press, New York.
- Colvin, J.S., Bohne, B.A., Harding, G.W., McEwen, D.G., and Ornitz, D.M. 1996. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. *Nat. Genet.* **12**: 390–397.
- Colvin, J.S., Feldman, B., Nadeau, J.H., Goldfarb, M., and Ornitz, D.M. 1999. Genomic organization and embryonic expression of the mouse fibroblast growth factor 9 gene. *Dev. Dyn.* **216**: 72–88.
- Colvin, J.S., Green, R.P., Schmahl, J., Capel, B., and Ornitz, D.M. 2001a. Male-to-female sex reversal in mice lacking fibroblast growth factor 9. *Cell* **104**: 875–889.
- Colvin, J.S., White, A., Pratt, S.J., and Ornitz, D.M. 2001b. Lung hypoplasia and neonatal death in *Fgf9*-null mice identify this gene as an essential regulator of lung mesenchyme. *Development* **128**: 2095–2106.
- Couly, G.F., Coltey, P.M., and Le Douarin, N.M. 1993. The triple origin of skull in higher vertebrates: A study in quail-chimeras. *Development* **117**: 409–429.
- DeBaun, M.R., Ess, J., and Saunders, S. 2001. Simpson Golabi Behmel syndrome: Progress toward understanding the molecular basis for overgrowth, malformation, and cancer predisposition. *Mol. Genet. Metab.* **72**: 279–286.
- Debiais, F., Hott, M., Graulet, A.M., and Marie, P.J. 1998. The effects of fibroblast growth factor-2 on human neonatal calvaria osteoblastic cells are differentiation stage specific. *J. Bone. Miner. Res.* **13**: 645–654.
- Debiais, F., Lemonnier, J., Hay, E., Delannoy, P., Caverzasio, J., and Marie, P.J. 2001. Fibroblast growth factor-2 (FGF-2) increases N-cadherin expression through protein kinase C and Src-kinase pathways in human calvaria osteoblasts. *J. Cell. Biochem.* **81**: 68–81.
- Delaney, A.M. and Canalis, E. 1998. Dual regulation of stromelysin-3 by fibroblast growth factor-murine osteoblasts. *J. Biol. Chem.* **273**: 16595–16600.
- deLapeyriere, O., Ollendorff, V., Planche, J., Ott, M.O., Pizette, S., Coulrier, F., and Birnbaum, D. 1993. Expression of the *Fgf6* gene is restricted to developing skeletal muscle in the mouse embryo. *Development* **118**: 601–611.
- Delezoide, A.L., Benoistclasselin, C., Legeaimallet, L., Lemerrer, M., Munnich, A., Vekemans, M., and Bonaventure, J. 1998. Spatio-temporal expression of *Fgfr* 1, 2 and 3 genes during human embryo-fetal ossification. *Mech. Dev.* **77**: 19–30.
- Deng, C.X., Wynshaw-Boris, A., Shen, M.M., Daugherty, C., Ornitz, D.M., and Leder, P. 1994. Murine FGFR-1 is required for early postimplantation growth and axial organization. *Genes & Dev.* **8**: 3045–3057.
- Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A., and Leder, P. 1996. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. *Cell* **84**: 911–921.
- De Pollack, C., Renierm, D., Hott, M., and Marie, P.J. 1996. Increased bone formation and osteoblastic cell phenotype in premature cranial suture ossification (craniosynostosis). *J. Bone. Miner. Res.* **11**: 401–407.
- Dodig, M., Tadic, T., Kronenberg, M.S., Dacic, S., Liu, Y.H., Maxson, R., Rowe, D.W., and Lichtler, A.C. 1999. Ectopic *Msx2* overexpression inhibits and *Msx2* antisense stimulates calvarial osteoblast differentiation. *Dev. Biol.* **209**: 298–307.
- Ducy, P., Zhang, R., Geoffroy, V., Ridall, A.L., and Karsenty, G. 1997. *Osf2/Cbfa1*: A transcriptional activator of osteoblast differentiation. *Cell* **89**: 747–754.
- Duprez, D., Bell, E.J., Richardson, M.K., Archer, C.W., Wolpert, L., Brickell, P.M., and Francis-West, P.H. 1996. Overexpression of BMP-2 and BMP-4 alters the size and shape of developing skeletal elements in the chick limb. *Mech. Dev.* **57**: 145–157.
- el Ghouzzi, V., Le Merrer, M., Perrin-Schmitt, F., Lajeunie, E., Benit, P., Renier, D., Bourgeois, P., Bolcato-Bellemin, A.L., Munnich, A., and Bonaventure, J. 1997. Mutations of the TWIST gene in the Saethre-Chotzen syndrome. *Nat. Genet.* **15**: 42–46.
- Ellsworth, J.L., Berry, J., Bukowski, T., Claus, J., Feldhaus, A., Holderman, S., Holdren, M.S., Lum, K.D., Moore, E.E., Raymond, F., et al. 2002. Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors. *Osteoarthritis Cart.* **10**: 308–320.
- Fang, M.A., Glackin, C.A., Sadhu, A., and McDougall, S. 2001. Transcriptional regulation of $\alpha 2(1)$ collagen gene expression by fibroblast growth factor-2 in MC3T3-E1 osteoblast-like cells. *J. Cell. Biochem.* **80**: 550–559.
- Finch, P.W., Cunha, G.R., Rubin, J.S., Wong, J., and Ron, D. 1995. Pattern of keratinocyte growth factor and keratinocyte growth factor receptor expression during mouse fetal development suggests a role in mediating morphogenetic mesenchymal-epithelial interactions. *Dev. Dyn.* **203**: 223–240.
- Fiore, F., Planche, J., Gibier, P., Sebillé, A., Delapeyrière, O., and Birnbaum, D. 1997. Apparent normal phenotype of *Fgf6*^{-/-} mice. *Int. J. Devel. Biol.* **41**: 639–642.
- Fragale, A., Tartaglia, M., Bernardini, S., Di Stasi, A.M., Di Rocco, C., Velardi, F., Teti, A., Battaglia, P.A., and Migliaccio, S. 1999. Decreased proliferation and altered differentiation in osteoblasts from genetically and clinically distinct craniosynostotic disorders. *Am. J. Pathol.* **154**: 1465–1477.
- Galvin, B.D., Hart, K.C., Meyer, A.N., Webster, M.K., and Donoghue, D.J. 1996. Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras. *Proc. Natl. Acad. Sci.* **93**: 7894–7899.
- Garofalo, S., Kliger-Spatz, M., Cooke, J.L., Wolstin, O., Lunstrum, G.P., Moshkovitz, S.M., Horton, W.A., and Yayon, A. 1999. Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice. *J. Bone. Miner. Res.* **14**: 1909–1915.
- Gorry, M.C., Preston, R.A., White, G.J., Zhang, Y., Singhal,

- V.K., Losken, H.W., Parker, M.G., Nwokoro, N.A., Post, J.C., and Ehrlich, G.D. 1995. Crouzon syndrome: Mutations in two spliceoforms of FGFR2 and a common point mutation shared with Jackson-Weiss syndrome. *Hum. Mol. Genet.* **4**: 1387–1390.
- Greenwald, J.A., Mehrara, B.J., Spector, J.A., Warren, S.M., Fagenholz, P.J., Smith, L.E., Bouletreau, P.J., Crisera, F.E., Ueno, H., and Longaker, M.T. 2001. In vivo modulation of FGF biological activity alters cranial suture fate. *Am. J. Pathol.* **158**: 441–452.
- Guimond, S.E. and Turnbull, J.E. 1999. Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides. *Curr. Biol.* **9**: 1343–1346.
- Guo, L., Degenstein, L., and Fuchs, E. 1996. Keratinocyte growth factor is required for hair development but not for wound healing. *Genes & Dev.* **10**: 165–175.
- Haaijman, A., Karperien, M., Lanske, B., Hendriks, J., Lowik, C.W., Bronckers, A.L., and Burger, E.H. 1999. Inhibition of terminal chondrocyte differentiation by bone morphogenetic protein 7 (OP-1) in vitro depends on the periarticular region but is independent of parathyroid hormone-related peptide. *Bone* **25**: 397–404.
- Hajihosseini, M.K. and Heath, J.K. 2002. Expression patterns of fibroblast growth factors-18 and -20 in mouse embryos is suggestive of novel roles in calvarial and limb development. *Mech. Dev.* **113**: 79–83.
- Hajihosseini, M.K., Wilson, S., De Moerloose, L., and Dickson, C. 2001. A splicing switch and gain-of-function mutation in Fgfr2-IIIc hemizygotes causes Apert/Pfeiffer-syndrome-like phenotypes. *Proc. Natl. Acad. Sci.* **98**: 3855–3860.
- Hall, B.K. 1987. Earliest evidence of cartilage and bone development in embryonic life. *Clin. Orthop.* **225**: 255–272.
- Hall, B.K. and Miyake, T. 1992. The membranous skeleton: The role of cell condensations in vertebrate skeletogenesis. *Anat. Embryol. (Berl.)* **186**: 107–124.
- . 2000. All for one and one for all: Condensations and the initiation of skeletal development. *Bioessays* **22**: 138–147.
- Hart, K.C., Robertson, S.C., Kanemitsu, M.Y., Meyer, A.N., Tynan, J.A., and Donoghue, D.J. 2000. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. *Oncogene* **19**: 3309–3320.
- Haub, O. and Goldfarb, M. 1991. Expression of the fibroblast growth factor-5 gene in the mouse embryo. *Development* **112**: 397–406.
- Hay, E., Hott, M., Graulet, A.M., Lomri, A., and Marie, P.J. 1999. Effects of bone morphogenetic protein-2 on human neonatal calvaria cell differentiation. *J. Cell. Biochem.* **72**: 81–93.
- Hay, E., Lemonnier, J., Fromigue, O., and Marie, P.J. 2001. Bone morphogenetic protein-2 promotes osteoblast apoptosis through a Smad-independent, protein kinase C-dependent signaling pathway. *J. Biol. Chem.* **276**: 29028–29036.
- Hebert, J.M., Rosenquist, T., Gotz, J., and Martin, G.R. 1994. FGF5 as a regulator of the hair growth cycle: Evidence from targeted and spontaneous mutations. *Cell* **78**: 1017–1025.
- Henderson, J.E., Naski, M.C., Aarts, M.M., Wang, D., Cheng, L., Goltzman, D., and Ornitz, D.M. 2000. Expression of FGFR3 with the G380R achondroplasia mutation inhibits proliferation and maturation of CFK2 chondrocytic cells. *J. Bone Miner. Res.* **15**: 155–165.
- Hill, P.A., Tumber, A., and Meikle, M.C. 1997. Multiple extracellular signals promote osteoblast survival and apoptosis. *Endocrinology* **138**: 3849–3858.
- Horton, W.A. 1997. Fibroblast growth factor receptor 3 and the human chondrodysplasias. *Curr. Opin. Pediatr.* **9**: 437–442.
- Howard, T.D., Paznekas, W.A., Green, E.D., Chiang, L.C., Ma, N., Ortiz de Luna, R.I., Garcia Delgado, C., Gonzalez-Ramos, M., Kline, A.D., and Jabs, E.W. 1997. Mutations in TWIST, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome. *Nat. Genet.* **15**: 36–41.
- Hughes, S.E. 1997. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. *J. Histochem. Cytochem.* **45**: 1005–1019.
- Hurley, M.M., Abreu, C., Gronowicz, G., Kawaguchi, H., and Lorenzo, J. 1994. Expression and regulation of basic fibroblast growth factor mRNA levels in mouse osteoblastic MC3T3-E1 cells. *J. Biol. Chem.* **269**: 9392–9396.
- Hurley, M.M., Abreu, C., and Hakeda, Y. 1995. Basic fibroblast growth factor regulates IGF-I binding proteins in the clonal osteoblastic cell line MC3T3-E1. *J. Bone. Miner. Res.* **10**: 222–230.
- Hurley, M.M., Marcello, K., Abreu, C., and Kessler, M. 1996. Signal transduction by basic fibroblast growth factor in rat osteoblastic Pyla cells. *J. Bone. Miner. Res.* **11**: 1256–1263.
- Hurley, M.M., Lee, S.K., Raisz, L.G., Bernecker, P., and Lorenzo, J. 1998. Basic fibroblast growth factor induces osteoclast formation in murine bone marrow cultures. *Bone* **22**: 309–316.
- Hurley, M.M., Tetradis, S., Huang, Y.F., Hock, J., Kream, B.E., Raisz, L.G., and Sabbieti, M.G. 1999. Parathyroid hormone regulates the expression of fibroblast growth factor-2 mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells. *J. Bone. Miner. Res.* **14**: 776–783.
- Hurley, M.M., Marie, P.J., and Florkiewicz, R.Z. 2001. Fibroblast growth factors and receptor families in bone. In *Principles of bone biology* (eds. J.P. Bilezikian et al.), pp. 825–851. Academic Press, London, UK.
- Ibrahimi, O.A., Eliseenkova, A.V., Plotnikov, A.N., Yu, K., Ornitz, D.M., and Mohammadi, M. 2001. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. *Proc. Natl. Acad. Sci.* **5**: 5.
- Ikegawa, S., Fukushima, Y., Isomura, M., Takada, F., and Nakamura, Y. 1995. Mutations of the fibroblast growth factor receptor-3 gene in one familial and six sporadic cases of achondroplasia in Japanese patients. *Hum. Genet.* **96**: 309–311.
- Iseki, S., Wilkie, A.O.M., Heath, J.K., Ishimaru, T., Eto, K., and Morrisskay, G.M. 1997. Fgfr2 and osteopontin domains in the developing skull vault are mutually exclusive and can be altered by locally applied FGF2. *Development* **124**: 3375–3384.
- Iseki, S., Wilkie, A.O., and Morriss-Kay, G.M. 1999. Fgfr1 and Fgfr2 have distinct differentiation- and proliferation-related roles in the developing mouse skull vault. *Development* **126**: 5611–5620.
- Iwasaki, M., Le, A.X., and Helms, J.A. 1997. Expression of Indian hedgehog, bone morphogenetic protein 6 and gli during skeletal morphogenesis. *Mech. Dev.* **69**: 197–202.
- Iwata, T., Chen, L., Li, C., Ovchinnikov, D.A., Behringer, R.R., Francomano, C.A., and Deng, C.X. 2000. A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos. *Hum. Mol. Genet.* **9**: 1603–1613.
- Iwata, T., Li, C.L., Deng, C.X., and Francomano, C.A. 2001. Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice. *Hum. Mol. Genet.* **10**: 1255–1264.
- Jabs, E.W., Muller, U., Li, X., Ma, L., Luo, W., Haworth, I.S., Klisak, I., Sparkes, R., Warman, M.L., Mulliken, J.B., et al. 1993. A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis. *Cell* **75**: 443–450.

- Jabs, E.W., Li, X., Scott, A.F., Meyers, G., Chen, W., Eccles, M., Mao, J., Charnas, L.R., Jackson, C.E., and Jaye, M. 1994. Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. *Nat. Genet.* **8**: 275–279.
- Johnson, D.E. and Williams, L.T. 1993. Structural and functional diversity in the FGF receptor multigene family. *Adv. Cancer Res.* **60**: 1–41.
- Johnson, D., Iseki, S., Wilkie, A.O., and Morriss-Kay, G.M. 2000. Expression patterns of Twist and Fgfr1, -2 and -3 in the developing mouse coronal suture suggest a key role for Twist in suture initiation and biogenesis. *Mech. Dev.* **91**: 341–345.
- Kan, S.H., Elanko, N., Johnson, D., Cornejo-Roldan, L., Cook, J., Reich, E.W., Tomkins, S., Verloes, A., Twigg, S.R., Rannan-Eliya, S., et al. 2002. Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis. *Am. J. Hum. Genet.* **70**: 472–486.
- Karaplis, A.C. and Goltzman, D. 2000. PTH and PTHrP effects on the skeleton. *Rev. Endocr. Metab. Disord.* **1**: 331–341.
- Karaplis, A.C., Luz, A., Glowacki, J., Bronson, R.T., Tybulewicz, V.L.J., Kronenberg, H.M., and Mulligan, R.C. 1994. Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. *Genes & Dev.* **8**: 277–289.
- Karp, S.J., Schipani, E., St-Jacques, B., Hunzelman, J., Kronenberg, H., and McMahon, A.P. 2000. Indian hedgehog coordinates endochondral bone growth and morphogenesis via parathyroid hormone related-protein-dependent and -independent pathways. *Development* **127**: 543–548.
- Karsenty, G. and Wagner, E.F. 2002. Reaching a genetic and molecular understanding of skeletal development. *Dev. Cell* **2**: 389–406.
- Kawaguchi, H., Chikazu, D., Nakamura, K., Kumegawa, M., and Hakeda, Y. 2000. Direct and indirect actions of fibroblast growth factor 2 on osteoclastic bone resorption in cultures. *J. Bone. Miner. Res.* **15**: 466–473.
- Kawakami, Y., Ishikawa, T., Shimabara, M., Tanda, N., Enomoto-Iwamoto, M., Iwamoto, M., Kuwana, T., Ueki, A., Noji, S., and Nohno, T. 1996. BMP signaling during bone pattern determination in the developing limb. *Development* **122**: 3557–3566.
- Kim, H.J., Rice, D.P., Kettunen, P.J., and Thesleff, I. 1998. FGF-, BMP- and Shh-mediated signalling pathways in the regulation of cranial suture morphogenesis and calvarial bone development. *Development* **125**: 1241–1251.
- Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R.T., Gao, Y.H., Inada, M., et al. 1997. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. *Cell* **89**: 755–764.
- Kosher, R.A., Kulyk, W.M., and Gay, S.W. 1986. Collagen gene expression during limb cartilage differentiation. *J. Cell Biol.* **102**: 1151–1156.
- Kozawa, O., Tokuda, H., Matsuno, H., and Uematsu, T. 1999. Involvement of p38 mitogen-activated protein kinase in basic fibroblast growth factor-induced interleukin-6 synthesis in osteoblasts. *J. Cell. Biochem.* **74**: 479–485.
- Kronenberg, H.M. and Chung, U. 2001. The parathyroid hormone-related protein and Indian hedgehog feedback loop in the growth plate. *Novartis Found. Symp.* **232**: 144–157.
- Lajeunie, E., Ma, H.W., Bonaventure, J., Munnich, A., and LeMerrer, M. 1995. FGFR2 mutations in Pfeiffer syndrome. *Nat. Genet.* **9**: 108.
- Lajeunie, E., Catala, M., and Renier, D. 1999. Craniosynostosis: From a clinical description to an understanding of bone formation of the skull. *Childs Nerv. Syst.* **15**: 676–680.
- Lanske, B., Karaplis, A.C., Lee, K., Luz, A., Vortkamp, A., Pirro, A., Karperien, M., Defize, L.H.K., Ho, C., Mulligan, R.C., et al. 1996. PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. *Science* **273**: 663–666.
- Lee, B., Thirunavukkarasu, K., Zhou, L., Pastore, L., Baldini, A., Hecht, J., Geoffroy, V., Ducy, P., and Karsenty, G. 1997. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. *Nat. Genet.* **16**: 307–310.
- Lee, K., Deeds, J.D., and Segre, G.V. 1995. Expression of parathyroid hormone-related peptide and its receptor messenger ribonucleic acids during fetal development of rats. *Endocrinology* **136**: 453–463.
- Legeai-Mallet, L., Benoist-Lasselin, C., Delezoide, A.L., Munnich, A., and Bonaventure, J. 1998. Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. *J. Biol. Chem.* **273**: 13007–13014.
- Lemonnier, J., Delannoy, P., Hott, M., Lomri, A., Modrowski, D., and Marie, P.J. 2000. The Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent downregulation of FGFR-2 associated with premature calvaria osteoblast differentiation. *Exp. Cell Res.* **256**: 158–167.
- Lemonnier, J., Hay, E., Delannoy, P., Fromiguet, O., Lomri, A., Modrowski, D., and Marie, P.J. 2001a. Increased osteoblast apoptosis in Apert craniosynostosis: Role of protein kinase C and interleukin-1. *Am. J. Pathol.* **158**: 1833–1842.
- Lemonnier, J., Hay, E., Delannoy, P., Lomri, A., Modrowski, D., Caverzasio, J., and Marie, P.J. 2001b. Role of N-cadherin and protein kinase C in osteoblast gene activation induced by the S252W fibroblast growth factor receptor 2 mutation in Apert craniosynostosis. *J. Bone. Miner. Res.* **16**: 832–845.
- Li, C., Chen, L., Iwata, T., Kitagawa, M., Fu, X.Y., and Deng, C.X. 1999. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. *Hum. Mol. Genet.* **8**: 35–44.
- Li, Y., Mangasarian, K., Mansukhani, A., and Basilico, C. 1997. Activation of FGF receptors by mutations in the transmembrane domain. *Oncogene* **14**: 1397–1406.
- Lin, H.Y., Xu, J.S., Ornitz, D.M., Halegoua, S., and Hayman, M.J. 1996. The fibroblast growth factor receptor-1 is necessary for the induction of neurite outgrowth in PC12 cells by aFGF. *J. Neurosci.* **16**: 4579–4587.
- Liu, Y.H., Kundu, R., Wu, L., Luo, W., Ignelzi, Jr., M.A., Snead, M.L., and Maxson, Jr., R.E. 1995. Premature suture closure and ectopic cranial bone in mice expressing Msx2 transgenes in the developing skull. *Proc. Natl. Acad. Sci.* **92**: 6137–6141.
- Liu, Y.H., Tang, Z., Kundu, R.K., Wu, L., Luo, W., Zhu, D., Sangiorgi, F., Snead, M.L., and Maxson, R.E. 1999. Msx2 gene dosage influences the number of proliferative osteogenic cells in growth centers of the developing murine skull: A possible mechanism for MSX2-mediated craniosynostosis in humans. *Dev. Biol.* **205**: 260–274.
- Liu, Z., Xu, J., Colvin, J.S., and Ornitz, D.M. 2002. Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. *Genes & Dev.* **16**: 859–869.
- Lomri, A., Lemonnier, J., Hott, M., de Parseval, N., Lajeunie, E., Munnich, A., Renier, D., and Marie, P.J. 1998. Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome. *J. Clin. Invest.* **101**: 1310–1317.
- Lomri, A., Lemonnier, J., Delannoy, P., and Marie, P.J. 2001.

- Increased expression of protein kinase C α , interleukin-1 α , and RhoA guanosine 5'-triphosphatase in osteoblasts expressing the Ser252Trp fibroblast growth factor 2 Apert mutation: Identification by analysis of complementary DNA microarray. *J. Bone. Miner. Res.* **16**: 705–712.
- Long, F. and Linsenmayer, T.F. 1998. Regulation of growth region cartilage proliferation and differentiation by perichondrium. *Development* **125**: 1067–1073.
- Malcolm, S. and Reardon, W. 1996. Fibroblast growth factor receptor-2 mutations in craniosynostosis. *Ann. NY Acad. Sci.* **785**: 164–170.
- Mangasarian, K., Li, Y., Mansukhani, A., and Basilico, C. 1997. Mutation associated with Crouzon syndrome causes ligand-independent dimerization and activation of FGF receptor-2. *J. Cell. Physiol.* **172**: 117–125.
- Mansukhani, A., Bellosta, P., Sahni, M., and Basilico, C. 2000. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. *J. Cell Biol.* **149**: 1297–1308.
- Marie, P.J., Lomri, A., Debais, F., and Lemonnier, J. 2000. Fibroblast growth factors and osteogenesis. In *Skeletal growth factors* (ed. E. Canalis), pp. 179–196. Lippincott Williams and Wilkins, Philadelphia.
- Marie, P.J., Debais, F., and Hay, E. 2002. Regulation of human cranial osteoblast phenotype by FGF-2, FGFR-2 and BMP-2 signaling. *Histol. Histopathol.* **17**: 877–885.
- Martin, G.R. 1998. The roles of FGFs in the early development of vertebrate limbs. *Genes & Dev.* **12**: 1571–1586.
- Mason, I.J., Fuller-Pace, F., Smith, R., and Dickson, C. 1994. FGF-7 (keratinocyte growth factor) expression during mouse development suggests roles in myogenesis, forebrain regionalisation and epithelial-mesenchymal interactions. *Mech. Dev.* **45**: 15–30.
- Mathijssen, I.M., van Leeuwen, H., Vermeij-Keers, C., and Vaandrager, J.M. 2001. FGF-4 or FGF-2 administration induces apoptosis, collagen type I expression, and mineralization in the developing coronal suture. *J. Craniofac. Surg.* **12**: 399–400.
- Mehrra, B.J., Mackool, R.J., McCarthy, J.G., Gittes, G.K., and Longaker, M.T. 1998. Immunolocalization of basic fibroblast growth factor and fibroblast growth factor receptor-1 and receptor-2 in rat cranial sutures. *Plast. Reconstr. Surg.* **102**: 1805–1820.
- Meyers, E.N., Lewandoski, M., and Martin, G.R. 1998. An *Fgf8* mutant allelic series generated by Cre- and Flp-mediated recombination. *Nat. Genet.* **18**: 136–141.
- Meyers, G.A., Orlow, S.J., Munro, I.R., Przylepa, K.A., and Jabs, E.W. 1995. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. *Nat. Genet.* **11**: 462–464.
- Meyers, G.A., Day, D., Goldberg, R., Daentl, D.L., Przylepa, K.A., Abrams, L.J., Graham, Jr., J.M., Feingold, M., Moeschler, J.B., Rawnsley, E., et al. 1996. FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: Evidence for missense changes, insertions, and a deletion due to alternative RNA splicing. *Am. J. Hum. Genet.* **58**: 491–498.
- Miki, T., Bottaro, D.P., Fleming, T.P., Smith, C.L., Burgess, W.H., Chan, A.M., and Aaronson, S.A. 1992. Determination of ligand-binding specificity by alternative splicing: Two distinct growth factor receptors encoded by a single gene. *Proc. Natl. Acad. Sci.* **89**: 246–250.
- Minina, E., Wenzel, H.M., Kreschel, C., Karp, S., Gaffield, W., McMahon, A.P., and Vortkamp, A. 2001. BMP and Ihh/PTHrP signaling interact to coordinate chondrocyte proliferation and differentiation. *Development* **128**: 4523–4534.
- Mohammadi, M., Schlessinger, J., and Hubbard, S.R. 1996. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. *Cell* **86**: 577–587.
- Molteni, A., Modrowski, D., Hott, M., and Marie, P.J. 1999. Differential expression of fibroblast growth factor receptor-1, -2, and -3 and syndecan-1, -2, and -4 in neonatal rat mandibular condyle and calvaria during osteogenic differentiation in vitro. *Bone* **24**: 337–347.
- Monsonigo-Orman, E., Adar, R., Feferman, T., Segev, O., and Yayon, A. 2000. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. *Mol. Cell. Biol.* **20**: 516–522.
- Montero, A., Okada, Y., Tomita, M., Ito, M., Tsurukami, H., Nakamura, T., Doetschman, T., Coffin, J.D., and Hurley, M.M. 2000. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. *J. Clin. Invest.* **105**: 1085–1093.
- Moore, R., Ferretti, P., Copp, A., and Thorogood, P. 2002. Blocking endogenous FGF-2 activity prevents cranial osteogenesis. *Dev. Biol.* **243**: 99–114.
- Morris-Kay, G.M., Iseki, S., and Johnson, D. 2001. Genetic control of the cell proliferation-differentiation balance in the developing skull vault: Roles of fibroblast growth factor receptor signalling pathways. *Novartis Found. Symp.* **232**: 102–121.
- Most, D., Levine, J.P., Chang, J., Sung, J., McCarthy, J.G., Schendel, S.A., and Longaker, M.T. 1998. Studies in cranial suture biology: Up-regulation of transforming growth factor- β 1 and basic fibroblast growth factor mRNA correlates with posterior frontal cranial suture fusion in the rat. *Plast. Reconstr. Surg.* **101**: 1431–1440.
- Muenke, M. and Schell, U. 1995. Fibroblast-growth-factor receptor mutations in human skeletal disorders. *Trends. Genet.* **11**: 308–313.
- Muenke, M., Schell, U., Hehr, A., Robin, N.H., Losken, H.W., Schinzel, A., Pulley, L.J., Rutland, P., Reardon, W., Malcolm, S., et al. 1994. A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. *Nat. Genet.* **8**: 269–274.
- Mundlos, S., Otto, F., Mundlos, C., Mulliken, J.B., Aylsworth, A.S., Albright, S., Lindhout, D., Cole, W.G., Henn, W., Knoll, J.H., et al. 1997. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. *Cell* **89**: 773–779.
- Mundy, G., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B., Zhao, M., and Gutierrez, G. 1999. Stimulation of bone formation in vitro and in rodents by statins. *Science* **286**: 1946–1949.
- Murakami, S., Kan, M., McKeehan, W.L., and de Crombrughe, B. 2000. Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway. *Proc. Natl. Acad. Sci.* **97**: 1113–1118.
- Nah, H.D., Rodgers, B.J., Kulyk, W.M., Kream, B.E., Kosher, R.A., and Upholt, W.B. 1988. In situ hybridization analysis of the expression of the type II collagen gene in the developing chicken limb bud. *Coll. Relat. Res.* **8**: 277–294.
- Nakagawa, N., Yasuda, H., Yano, K., Mochizuki, S., Kobayashi, N., Fujimoto, H., Shima, N., Morinaga, T., Chikazu, D., Kawaguchi, H., et al. 1999. Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells. *Biochem. Biophys. Res. Commun.* **265**: 158–163.
- Naski, M.C. and Ornitz, D.M. 1998. FGF signaling in skeletal

- development. *Front. Biosci.* **3**: D781–D794.
- Naski, M.C., Wang, Q., Xu, J., and Ornitz, D.M. 1996. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. *Nat. Genet.* **13**: 233–237.
- Naski, M.C., Colvin, J.S., Coffin, J.D., and Ornitz, D.M. 1998. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. *Development* **125**: 4977–4988.
- Neilson, K.M. and Friesel, R.E. 1995. Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome. *J. Biol. Chem.* **270**: 26037–26040.
- Newberry, E.P., Boudreaux, J.M., and Towler, D.A. 1996. The rat osteocalcin fibroblast growth factor (FGF)-responsive element: An okadaic acid-sensitive, FGF-selective transcriptional response motif. *Mol. Endocrinol.* **10**: 1029–1040.
- Newberry, E.P., Willis, D., Latifi, T., Boudreaux, J.M., and Towler, D.A. 1997. Fibroblast growth factor receptor signaling activates the human interstitial collagenase promoter via the bipartite Ets-AP1 element. *Mol. Endocrinol.* **11**: 1129–1144.
- Newberry, E.P., Latifi, T., and Towler, D.A. 1998. Reciprocal regulation of osteocalcin transcription by the homeodomain proteins *Msx2* and *Dlx5*. *Biochemistry* **37**: 16360–16368.
- . 1999. The RRM domain of MINT, a novel *Msx2* binding protein, recognizes and regulates the rat osteocalcin promoter. *Biochemistry* **38**: 10678–10690.
- Noda, M. and Vogel, R. 1989. Fibroblast growth factor enhances type β 1 transforming growth factor gene expression in osteoblast-like cells. *J. Cell Biol.* **109**: 2529–2535.
- Noden, D.M. 1992. Vertebrate craniofacial development: Novel approaches and new dilemmas. *Curr. Opin. Genet. Dev.* **2**: 576–581.
- Ohbayashi, N., Shibayama, M., Kurotaki, Y., Imanishi, M., Fujimori, T., Itoh, N., and Takada, S. 2002. FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. *Genes & Dev.* **16**: 870–879.
- Oldridge, M., Wilkie, A.O., Slaney, S.F., Poole, M.D., Pulleyn, L.J., Rutland, P., Hockley, A.D., Wake, M.J., Goldin, J.H., Winter, R.M., et al. 1995. Mutations in the third immunoglobulin domain of the fibroblast growth factor receptor-2 gene in Crouzon syndrome. *Hum. Mol. Genet.* **4**: 1077–1082.
- Olsen, B.R., Reginato, A.M., and Wang, W. 2000. Bone development. *Annu. Rev. Cell Dev. Biol.* **16**: 191–220.
- Opperman, L.A. 2000. Cranial sutures as intramembranous bone growth sites. *Dev. Dyn.* **219**: 472–485.
- Ornitz, D.M. 2000. FGFs, heparan sulfate and FGFRs: Complex interactions essential for development. *Bioessays* **22**: 108–112.
- . 2001. Regulation of chondrocyte growth and differentiation by fibroblast growth factor receptor 3. *Novartis Found. Symp.* **232**: 63–80; 272–282.
- Ornitz, D.M. and Itoh, N. 2001. Fibroblast growth factors. *Genome Biol.* **2**: Reviews 3005.
- Ornitz, D.M., Yayon, A., Flanagan, J.G., Svahn, C.M., Levi, E., and Leder, P. 1992. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. *Mol. Cell. Biol.* **12**: 240–247.
- Ornitz, D.M., Xu, J., Colvin, J.S., McEwen, D.G., MacArthur, C.A., Coulier, F., Gao, G., and Goldfarb, M. 1996. Receptor specificity of the fibroblast growth factor family. *J. Biol. Chem.* **271**: 15292–15297.
- Orr-Urtreger, A., Givol, D., Yayon, A., Yarden, Y., and Lonai, P. 1991. Developmental expression of two murine fibroblast growth factor receptors, *flg* and *bek*. *Development* **113**: 1419–1434.
- Orr-Urtreger, A., Bedford, M.T., Burakova, T., Arman, E., Zimmer, Y., Yayon, A., Givol, D., and Lonai, P. 1993. Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). *Dev. Biol.* **158**: 475–486.
- Pandit, S.G., Govindraj, P., Sasse, J., Neame, P.J., and Hassell, J.R. 2002. The fibroblast growth factor receptor, FGFR3, forms gradients of intact and degraded protein across the growth plate of developing bovine ribs. *Biochem. J.* **361**: 231–241.
- Park, W.J., Meyers, G.A., Li, X., Theda, C., Day, D., Orlow, S.J., Jones, M.C., and Jabbs, E.W. 1995. Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability. *Hum. Mol. Genet.* **4**: 1229–1233.
- Pathi, S., Rutenberg, J.B., Johnson, R.L., and Vortkamp, A. 1999. Interaction of *Ihh* and BMP/Noggin signaling during cartilage differentiation. *Dev. Biol.* **209**: 239–253.
- Peters, K.G., Werner, S., Chen, G., and Williams, L.T. 1992. Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse. *Development* **114**: 233–243.
- Peters, K., Ornitz, D.M., Werner, S., and Williams, L. 1993. Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. *Dev. Biol.* **155**: 423–430.
- Plotnikov, A.N., Hubbard, S.R., Schlessinger, J., and Mohammadi, M. 2000. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. *Cell* **101**: 413–424.
- Przylepka, K.A., Paznekas, W., Zhang, M., Golabi, M., Bias, W., Bamshad, M.J., Carey, J.C., Hall, B.D., Stevenson, R., Orlow, S., et al. 1996. Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome. *Nat. Genet.* **13**: 492–494.
- Raffioni, S., Thomas, D., Foehr, E.D., Thompson, L.M., and Bradshaw, R.A. 1999. Comparison of the intracellular signaling responses by three chimeric fibroblast growth factor receptors in PC12 cells. *Proc. Natl. Acad. Sci.* **96**: 7178–7183.
- Rapraeger, A.C. 1995. In the clutches of proteoglycans: How does heparan sulfate regulate FGF binding? *Chem. Biol.* **2**: 645–649.
- Rapraeger, A.C., Krufka, A., and Olwin, B.B. 1991. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. *Science* **252**: 1705–1708.
- Reardon, W., Winter, R.M., Rutland, P., Pulleyn, L.J., Jones, B.M., and Malcolm, S. 1994. Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. *Nat. Genet.* **8**: 98–103.
- Rice, D.P., Kim, H.J., and Thesleff, I. 1999. Apoptosis in murine calvarial bone and suture development. *Eur. J. Oral. Sci.* **107**: 265–275.
- Rice, D.P.C., Aberg, T., Chan, Y.S., Tang, Z.Q., Kettunen, P.J., Pakarinen, L., Maxson, R.E., and Thesleff, I. 2000. Integration of FGF and TWIST in calvarial bone and suture development. *Development* **127**: 1845–1855.
- Robertson, S.C., Meyer, A.N., Hart, K.C., Galvin, B.D., Webster, M.K., and Donoghue, D.J. 1998. Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain. *Proc. Natl. Acad. Sci.* **95**: 4567–4572.
- Rousseau, F., Bonaventure, J., Legeal-Mallet, L., Pelet, A., Rozet, J.-M., Maroteaux, P., Le Merrer, M., and Munnich, A. 1994. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. *Nature* **371**: 252–254.
- Rousseau, F., Saugier, P., Le Merrer, M., Munnich, A.,

- Delezoide, A.L., Maroteaux, P., Bonaventure, J., Narcy, F., and Sanak, M. 1995. Stop codon FGFR3 mutations in thanatophoric dwarfism type I. *Nat. Genet.* **10**: 11–12.
- Rousseau, F., el Ghouzzi, V., Delezoide, A.L., Legeai-Mallet, L., Le Merrer, M., Munnich, A., and Bonaventure, J. 1996. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). *Hum. Mol. Genet.* **5**: 509–512.
- Rozenblatt-Rosen, O., Mosonogo-Ornan, E., Sadot, E., Madar-Shapiro, L., Sheinin, Y., Ginsberg, D., and Yayon, A. 2002. Induction of chondrocyte growth arrest by FGF: Transcriptional and cytoskeletal alterations. *J. Cell Sci.* **115**: 553–562.
- Rutland, P., Pulleyn, L.J., Reardon, W., Baraitser, M., Hayward, R., Jones, B., Malcolm, S., Winter, R.M., Oldridge, M., Slaney, S.F., et al. 1995. Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. *Nat. Genet.* **9**: 173–176.
- Saaddeh, P.B., Mehrara, B.J., Steinbrech, D.S., Spector, J.A., Greenwald, J.A., Chin, G.S., Ueno, H., Gittes, G.K., and Longaker, M.T. 2000. Mechanisms of fibroblast growth factor-2 modulation of vascular endothelial growth factor expression by osteoblastic cells. *Endocrinology* **141**: 2075–2083.
- Sabbieti, M.G., Marchetti, L., Abreu, C., Montero, A., Hand, A.R., Raisz, L.G., and Hurley, M.M. 1999. Prostaglandins regulate the expression of fibroblast growth factor-2 in bone. *Endocrinology* **140**: 434–444.
- Sahni, M., Ambrosetti, D.C., Mansukhani, A., Gertner, R., Levy, D., and Basilico, C. 1999. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. *Genes & Dev.* **13**: 1361–1366.
- Sahni, M., Raz, R., Coffin, J.D., Levy, D., and Basilico, C. 2001. STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. *Development* **128**: 2119–2129.
- Satokata, I., Ma, L., Ohshima, H., Bei, M., Woo, I., Nishizawa, K., Maeda, T., Takano, Y., Uchiyama, M., Heaney, S., et al. 2000. Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. *Nat. Genet.* **24**: 391–395.
- Savage, M.P. and Fallon, J.F. 1995. FGF-2 mRNA and its antisense message are expressed in a developmentally specific manner in the chick limb bud and mesonephros. *Dev. Dyn.* **202**: 343–353.
- Schedlich, L.J., Flanagan, J.L., Crofts, L.A., Gillies, S.A., Goldberg, D., Morrison, N.A., and Eisman, J.A. 1994. Transcriptional activation of the human osteocalcin gene by basic fibroblast growth factor. *J. Bone Miner. Res.* **9**: 143–152.
- Schell, U., Hehr, A., Feldman, G.J., Robin, N.H., Zackai, E.H., de Die-Smulders, C., Viskochil, D.H., Stewart, J.M., Wolff, G., Ohashi, H., et al. 1995. Mutations in FGFR1 and FGFR2 cause familial and sporadic Pfeiffer syndrome. *Hum. Mol. Genet.* **4**: 323–328.
- Schmid, T.M. and Linsenmayer, T.F. 1985. Immunohistochemical localization of short chain cartilage collagen (type X) in avian tissues. *J. Cell Biol.* **100**: 598–605.
- Segev, O., Chumakov, I., Nevo, Z., Givol, D., Madar-Shapiro, L., Sheinin, Y., Weinreb, M., and Yayon, A. 2000. Restrained chondrocyte proliferation and maturation with abnormal growth plate vascularization and ossification in human FGFR-3(G380R) transgenic mice. *Hum. Mol. Genet.* **9**: 249–258.
- Shevde, N.K., Bendixen, A.C., Maruyama, M., Li, B.L., and Billmire, D.A. 2001. Enhanced activity of osteoblast differentiation factor (PEBP2 α A2/CBFA1) in affected sutural osteoblasts from patients with nonsyndromic craniosynostosis. *Cleft Palate Craniofac. J.* **38**: 606–614.
- Shiang, R., Thompson, L.M., Zhu, Y.-Z., Church, D.M., Fielder, T.J., Bocian, M., Winokur, S.T., and Wasmuth, J.J. 1994. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. *Cell* **78**: 335–342.
- Shimoaka, T., Ogasawara, T., Yonamine, A., Chikazu, D., Kawano, H., Nakamura, K., Itoh, N., and Kawaguchi, H. 2001. Regulation of osteoblast, chondrocyte, and osteoclast functions by fibroblast growth factor (FGF)-18 in comparison with FGF-2 and FGF-10. *J. Biol. Chem.* **11**: 11.
- Stanescu, R., Stanescu, V., and Maroteaux, P. 1990. Homozygous achondroplasia: Morphologic and biochemical study of cartilage. *Am. J. Med. Genet.* **37**: 412–421.
- Stankiewicz, P., Thiele, H., Baldermann, C., Kruger, A., Giannakidis, I., Dorr, S., Werner, N., Kunz, J., Rappold, G.A., and Hansmann, I. 2001. Phenotypic findings due to trisomy 7p15.3-pter including the TWIST locus. *Am. J. Med. Genet.* **103**: 56–62.
- Steinberger, D., Mulliken, J.B., and Muller, U. 1995. Predisposition for cysteine substitutions in the immunoglobulin-like chain of FGFR2 in Crouzon syndrome. *Hum. Genet.* **96**: 113–115.
- St-Jacques, B., Hammerschmidt, M., and McMahon, A.P. 1999. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. *Genes & Dev.* **13**: 2072–2086.
- Su, W.C.S., Kitagawa, M., Xue, N.R., Xie, B., Garofalo, S., Cho, J., Deng, C.X., Horton, W.A., and Fu, X.Y. 1997. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. *Nature* **386**: 288–292.
- Sullivan, R. and Klagsbrun, M. 1985. Purification of cartilage-derived growth factor by heparin affinity chromatography. *J. Biol. Chem.* **260**: 2399–2403.
- Superti-Furga, A., Eich, G., Bucher, H.U., Wissner, J., Giedion, A., Gitzelmann, R., and Steinmann, B. 1995. A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia. *Eur. J. Pediatr.* **154**: 215–219.
- Suzuki, A., Palmer, G., Bonjour, J.P., and Caverzasio, J. 2000. Stimulation of sodium-dependent phosphate transport and signaling mechanisms induced by basic fibroblast growth factor in MC3T3-E1 osteoblast-like cells. *J. Bone Miner. Res.* **15**: 95–102.
- Szebenyi, G., Savage, M.P., Olwin, B.B., and Fallon, J.F. 1995. Changes in the expression of fibroblast growth factor receptors mark distinct stages of chondrogenesis in vitro and during chick limb skeletal patterning. *Dev. Dyn.* **204**: 446–456.
- Tang, K.T., Capparelli, C., Stein, J.L., Stein, G.S., Lian, J.B., Huber, A.C., Braverman, L.E., and DeVito, W.J. 1996. Acidic fibroblast growth factor inhibits osteoblast differentiation in vitro: Altered expression of collagenase, cell growth-related, and mineralization-associated genes. *J. Cell. Biochem.* **61**: 152–166.
- Tavormina, P.L., Rimoin, D.L., Cohn, D.H., Zhu, Y.Z., Shiang, R., and Wasmuth, J.J. 1995a. Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. *Hum. Mol. Genet.* **4**: 2175–2177.
- Tavormina, P.L., Shiang, R., Thompson, L.M., Zhu, Y., Wilkin, D.J., Lachman, R.S., Wilcox, W.R., Rimoin, D.L., Cohn, D.H., and Wasmuth, J.J. 1995b. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. *Nat. Genet.* **9**: 321–328.
- Tokuda, H., Kozawa, O., and Uematsu, T. 2000. Basic fibroblast growth factor stimulates vascular endothelial growth factor release in osteoblasts: Divergent regulation by p42/p44 mi-

- togen-activated protein kinase and p38 mitogen-activated protein kinase. *J. Bone. Miner. Res.* **15**: 2371–2379.
- Towler, D.A., Rutledge, S.J., and Rodan, G.A. 1994. Msx-2/Hox 8.1: A transcriptional regulator of the rat osteocalcin promoter. *Mol. Endocrinol.* **8**: 1484–1493.
- Vajo, Z., Francomano, C.A., and Wilkin, D.J. 2000. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: The achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. *Endocr. Rev.* **21**: 23–39.
- Varghese, S., Ramsby, M.L., Jeffrey, J.J., and Canalis, E. 1995. Basic fibroblast growth factor stimulates expression of interstitial collagenase and inhibitors of metalloproteinases in rat bone cells. *Endocrinology* **136**: 2156–2162.
- Varghese, S., Rydziel, S., and Canalis, E. 2000. Basic fibroblast growth factor stimulates collagenase-3 promoter activity in osteoblasts through an activator protein-1-binding site. *Endocrinology* **141**: 2185–2191.
- Vortkamp, A., Lee, K., Lanske, B., Segre, G.V., Kronenberg, H.M., and Tabin, C.J. 1996. Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. *Science* **273**: 613–622.
- Wagner, E.F. and Karsenty, G. 2001. Genetic control of skeletal development. *Curr. Opin. Genet. Dev.* **11**: 527–532.
- Wang, J.K., Gao, G., and Goldfarb, M. 1994. Fibroblast growth factor receptors have different signaling and mitogenic potentials. *Mol. Cell. Biol.* **14**: 181–188.
- Wang, Q., Green, R.P., Zhao, G., and Ornitz, D.M. 2001. Differential regulation of endochondral bone growth and joint development by FGFR1 and FGFR3 tyrosine kinase domains. *Development* **128**: 3867–3876.
- Wang, Y.C., Spatz, M.K., Kannan, K., Hayk, H., Avivi, A., Gorivodsky, M., Pines, M., Yayon, A., Lonai, P., and Givol, D. 1999. A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. *Proc. Natl. Acad. Sci.* **96**: 4455–4460.
- Webster, M.K. and Donoghue, D.J. 1996. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. *EMBO J.* **15**: 520–527.
- . 1997. FGFR activation in skeletal disorders: Too much of a good thing. *Trends Genet.* **13**: 178–182.
- Wilkie, A.O. 1997. Craniosynostosis—genes and mechanisms. *Hum. Mol. Genet.* **6**: 1647–1656.
- . 2000. Epidemiology and genetics of craniosynostosis. *Am. J. Med. Genet.* **90**: 82–83.
- Wilkie, A.O. and Morriss-Kay, G.M. 2001. Genetics of craniofacial development and malformation. *Nat. Rev. Genet.* **2**: 458–468.
- Wilkie, A.O.M., Morriss-Kay, G.M., Jones, E.Y., and Heath, J.K. 1995a. Functions of fibroblast growth factors and their receptors. *Curr. Biol.* **5**: 500–507.
- Wilkie, A.O.M., Slaney, S.F., Oldridge, M., Poole, M.D., Ashworth, G.J., Hockley, A.D., Hayward, R.D., David, D.J., Pulleyn, L.J., Rutland, P., et al. 1995b. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. *Nat. Genet.* **9**: 165–172.
- Wilkie, A.O., Tang, Z., Elanko, N., Walsh, S., Twigg, S.R., Hurst, J.A., Wall, S.A., Chrzanowska, K.H., and Maxson, Jr., R.E. 2000. Functional haploinsufficiency of the human homeobox gene MSX2 causes defects in skull ossification. *Nat. Genet.* **24**: 387–390.
- Xu, J., Lawshe, A., MacArthur, C.A., and Ornitz, D.M. 1999. Genomic structure, mapping, activity and expression of fibroblast growth factor 17. *Mech. Dev.* **83**: 165–178.
- Xu, J.S., Liu, Z.H., and Ornitz, D.M. 2000. Temporal and spatial gradients of Fgf8 and Fgf17 regulate proliferation and differentiation of midline cerebellar structures. *Development* **127**: 1833–1843.
- Yamaguchi, A., Komori, T., and Suda, T. 2000. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. *Endocr. Rev.* **21**: 393–411.
- Yayon, A., Klagsbrun, M., Esko, J.D., Leder, P., and Ornitz, D.M. 1991. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. *Cell* **64**: 841–848.
- Yousfi, M., Lasmoles, F., Lomri, A., Delannoy, P., and Marie, P.J. 2001. Increased bone formation and decreased osteocalcin expression induced by reduced Twist dosage in Saethre-Chotzen syndrome. *J. Clin. Invest.* **107**: 1153–1161.
- Yousfi, M., Lasmoles, F., El Ghouzzi, V., and Marie, P.J. 2002. Twist haploinsufficiency in Saethre-Chotzen syndrome induces calvarial osteoblast apoptosis due to increased TNF α expression and caspase-2 activation. *Hum. Mol. Genet.* **11**: 359–369.
- Yu, K. and Ornitz, D.M. 2001. Uncoupling fibroblast growth factor receptor 2 ligand binding specificity leads to Apert syndrome-like phenotypes. *Proc. Natl. Acad. Sci.* **98**: 3641–3643.
- Yu, K., Herr, A.B., Waksman, G., and Ornitz, D.M. 2000. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. *Proc. Natl. Acad. Sci.* **97**: 14536–14541.
- Zhou, Y.X., Xu, X., Chen, L., Li, C., Brodie, S.G., and Deng, C.X. 2000. A Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures. *Hum. Mol. Genet.* **9**: 2001–2008.
- Zou, H., Choe, K.M., Lu, Y., Massague, J., and Niswander, L. 1997. BMP signaling and vertebrate limb development. *Cold Spring Harb. Symp. Quant. Biol.* **62**: 269–272.

FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease

David M. Ornitz and Pierre J. Marie

Genes Dev. 2002, **16**:

Access the most recent version at doi:[10.1101/gad.990702](https://doi.org/10.1101/gad.990702)

References

This article cites 239 articles, 67 of which can be accessed free at:
<http://genesdev.cshlp.org/content/16/12/1446.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).